Drug	Recommendations
Abemaciclib	Do not use Paxlovid. Visit https://www.bjc.org/for-physicians/covid for alternatives. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration.
Abrocitinib Acetaminophen	Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration.
	Temporarily withhold concomitant medications if clinically appropriate. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise
Alfuzosin	stated, interacting medications should be held for 8 days from the first dose of Paxlovid. Very sensitive or narrow therapeutic index CYP3A4 drugs may need to be held for 10 days after the first dose of Paxlovid Temperarily withheld encomitant medications if clinically appropriate. CYP3A4 inhibition receives approximately 2 days after Paylovid is discontinued. Unless otherwise
Aliskiren	Temporarily withhold concomitant medications if clinically appropriate. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise stated, interacting medications should be held for 8 days from the first dose of Paxlovid. Very sensitive or narrow therapeutic index CYP3A4 drugs may need to be held for 10 days after the first dose of Paxlovid
Allopurinol	Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration.
Alprazolam (reduce by 50%)	Reduce concomitant medication dose, if clinically appropriate and monitor for adverse effects. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paxlovid.
Amiodarone	Do not use Paxlovid. Visit https://www.bjc.org/for-physicians/covid for alternatives.
Amitriptyline	Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration.
Amlodipine (reduce by 50%)	Reduce concomitant medication dose, if clinically appropriate and monitor for adverse effects. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paxlovid.
Apalutamide	Do not use Paxlovid. Visit https://www.bjc.org/for-physicians/covid for alternatives.
Apixaban (reduce by 50%)	Reduce concomitant medication dose, if clinically appropriate and monitor for adverse effects. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paxlovid.
Aripiprazole (reduce by 50%)	Reduce concomitant medication dose, if clinically appropriate and monitor for adverse effects. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paxlovid.
Aspirin	Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration.
Atenolol	Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration.
Atorvastatin	Temporarily withhold concomitant medications if clinically appropriate. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise stated, interacting medications should be held for 8 days from the first dose of Paxlovid. Very sensitive or narrow therapeutic index CYP3A4 drugs may need to be held for 10 days after the first dose of Paxlovid days after the first dose of Paxlovid.
Avanafil	Temporarily withhold concomitant medications if clinically appropriate. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise stated, interacting medications should be held for 8 days from the first dose of Paxlovid. Very sensitive or narrow therapeutic index CYP3A4 drugs may need to be held for
	10 days after the first dose of Paxlovid
Azithromycin Baricitinib	Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration.
Beclomethasone (inhaled)	Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration.
Benazepril	Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration.
Betamethasone	Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration.
Bisoprolol Bosentan	Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Do not use Paxlovid. Visit https://www.bjc.org/for-physicians/covid for alternatives.
	Reduce concomitant medication dose, if clinically appropriate and monitor for adverse effects. CVP3A4 inhibition resolves approximately 3 days after Paylovid is
Brexpiprazole (reduce by 50%) Bromocriptine	discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paxlovid. Do not use Paxlovid. Visit https://www.bjc.org/for-physicians/covid for alternatives.
Budesonide (inhaled)	Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration.
Bupropion	Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration.
Buspirone (reduce by 50%)	Reduce concomitant medication dose, if clinically appropriate and monitor for adverse effects. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paxlovid.
Cabergoline	Do not use Paxlovid. Visit https://www.bjc.org/for-physicians/covid for alternatives.
Caffeine	Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration.
Canagliflozin Captopril	Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration.
Carbamazepine	Do not use Paxlovid. Visit https://www.bjc.org/for-physicians/covid for alternatives.
Cariprazine (reduce by 50%)	Reduce concomitant medication dose, if clinically appropriate and monitor for adverse effects. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is
	terms where the second second intervention and intervention to a second second (second second s
Carvedilol	discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paxlovid. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration.
Carvedilol Celecoxib	
Celecoxib Ceritinib	Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Do not use Paxlovid. Visit https://www.bjc.org/for-physicians/covid for alternatives.
Celecoxib	Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration.
Celecoxib Ceritinib Cetirizine Chlordiazepoxide	Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Do not use Paxlovid. Visit https://www.bic.org/for-physicians/covid for alternatives. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with caution/monitoring. Abrupt discontinuation or rapid dose reduction of benzodiazepines may precipitate acute withdrawal reactions. The risk is greatest for patients who have been using higher doses of benzodiazepines over an extended period of time.
Celecoxib Ceritinib Cetirizine	Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Do not use Paxlovid. Visit https://www.bic.org/for-physicians/covid for alternatives. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with caution/monitoring. Abrupt discontinuation or rapid dose reduction of benzodiazepines may precipitate acute withdrawal reactions. The risk is greatest for patients who have been using higher doses of benzodiazepines over an extended period of time. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration.
Celecoxib Ceritinib Cetirizine Chlordiazepoxide Ciclesonide (inhaled)	Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Do not use Paxlovid. Visit https://www.bic.org/for-physicians/covid for alternatives. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Caution/monitoring. Abrupt discontinuation or rapid dose reduction of benzodiazepines may precipitate acute withdrawal reactions. The risk is greatest for patients who have been using higher doses of benzodiazepines over an extended period of time. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration.
Celecoxib Ceritinib Cetirizine Chlordiazepoxide Ciclesonide (inhaled) Cidofovir Cilostazol (50 mg bid)	Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Do not use Paxlovid. Visit https://www.bic.org/for-physicians/covid for alternatives. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with caution/monitoring. Abrupt discontinuation or rapid dose reduction of benzodiazepines may precipitate acute withdrawal reactions. The risk is greatest for patients who have been using higher doses of benzodiazepines over an extended period of time. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Reduce concomitant medication dose, if clinically appropriate and monitor for adverse effects. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paxlovid. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Reduce concomitant medication dose, if clinically appropriate and monitor for adverse effects. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is Reduce concomitant medication dose, if clinically appropriate and monitor for adverse effects. CYP3A4 inhibit
Celecoxib Ceritinib Cetirizine Chlordiazepoxide Ciclesonide (inhaled) Cidofovir Cilostazol (50 mg bid) Citalopram	Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Do not use Paxlovid. Visit https://www.bjc.org/for-physicians/covid for alternatives. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with caution/monitoring. Abrupt discontinuation or rapid dose reduction of benzodiazepines may precipitate acute withdrawal reactions. The risk is greatest for patients who have been using higher doses of benzodiazepines over an extended period of time. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Reduce concomitant medication dose, if clinically appropriate and monitor for adverse effects. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paxlovid. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-admin
Celecoxib Ceritinib Cetirizine Chlordiazepoxide Ciclesonide (inhaled) Cidofovir Cilostazol (50 mg bid) Citalopram Clarithromycin – consult pharmacist	Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Do not use Paxlovid. Visit https://www.bic.org/for-physicians/covid for alternatives. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with caution/monitoring. Abrupt discontinuation or rapid dose reduction of benzodiazepines may precipitate acute withdrawal reactions. The risk is greatest for patients who have been using higher doses of benzodiazepines over an extended period of time. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Reduce concomitant medication dose, if clinically appropriate and monitor for adverse effects. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paxlovid. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Reduce concomitant medication dose, if clinically appropriate and monitor for adverse effects. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is Reduce concomitant medication dose, if clinically appropriate and monitor for adverse effects. CYP3A4 inhibit
Celecoxib Ceritinib Cetirizine Chlordiazepoxide Ciclesonide (inhaled) Cidofovir Cilostazol (50 mg bid) Citalopram Clarithromycin – consult pharmacist Clobazam	Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Do not use Paxlovid. Visit https://www.bic.org/for-physicians/covid for alternatives. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with axion/monitoring. Abrupt discontinuation or rapid dose reduction of benzodiazepines may precipitate acute withdrawal reactions. The risk is greatest for patients who have been using higher doses of benzodiazepines over an extended period of time. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Reduce concomitant medication dose, if clinically appropriate and monitor for adverse effects. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paxlovid. Can be co-administered with caution/monitoring. Abrupt discontinuation or rapid dose reduction of benzodiazepines may precipitate acute withdrawal reactions. The risk is greatest for patients who have been using higher doses of benzodiazepines over an extended period of time. Can be co-administered with caution/monitoring. Abrupt discontinuation or rapid dose reduction of benzodiazepines may precipitate a
Celecoxib Ceritinib Cetirizine Chlordiazepoxide Ciclesonide (inhaled) Cidofovir Cilostazol (50 mg bid) Citalopram Clarithromycin – consult pharmacist Clobazam Clonazepam	Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Do not use Paxlovid. Visit https://www.bic.org/for-physicians/covid for alternatives. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with or rapid dose reduction of benzodiazepines may precipitate acute withdrawal reactions. The risk is greatest for patients who have been using higher doses of benzodiazepines over an extended period of time. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Reduce concomitant medication dose, if clinically appropriate and monitor for adverse effects. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paxlovid. Can be co-administered with caution/monitoring. Abrupt discontinuation or rapid dose reduction of benzodiazepines may precipitate acute withdrawal reactions. The risk is greatest f
Celecoxib Ceritinib Cetirizine Chlordiazepoxide Ciclesonide (inhaled) Cidofovir Cilostazol (50 mg bid) Citalopram Clarithromycin – consult pharmacist Clobazam Clonazepam Clonidine	Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Caution/monitoring. Abrupt discontinuation or rapid dose reduction of benzodiazepines may precipitate acute withdrawal reactions. The risk is greatest for patients who have been using higher doses of benzodiazepines over an extended period of time. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Reduce concomitant medication dose, if clinically appropriate and monitor for adverse effects. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paxlovid. Can be co-administered with Caution/monitoring. Abrupt discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paxlovid is discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paxlovid is discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8
Celecoxib Ceritinib Cetirizine Chlordiazepoxide Ciclesonide (inhaled) Cidofovir Cilostazol (50 mg bid) Citalopram Clarithromycin – consult pharmacist Clobazam Clonazepam	Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Bo not use Paxlovid. Visit https://www.bic.org/for-physicians/covid for alternatives. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Caution/monitoring. Abrupt discontinuation or rapid dose reduction of benzodiazepines may precipitate acute withdrawal reactions. The risk is greatest for patients who have been using higher doses of benzodiazepines over an extended period of time. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Reduce concomitant medication dose, if clinically appropriate and monitor for adverse effects. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paxlovid. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Reduce concomitant medication dose, if clinically appropriate and monitor for adverse effects. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paxlovid. Can be co-administered with caution/monitoring. Abrupt discontinuation or rapid dose r
Celecoxib Ceritinib Cetirizine Chlordiazepoxide Ciclesonide (inhaled) Cidofovir Cilostazol (50 mg bid) Citalopram Clarithromycin – consult pharmacist Clobazam Clonazepam Clonidine	Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Caution/monitoring. Abrupt discontinuation or rapid dose reduction of benzodiazepines may precipitate acute withdrawal reactions. The risk is greatest for patients who have been using higher doses of benzodiazepines over an extended period of time. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Reduce concomitant medication dose, if clinically appropriate and monitor for adverse effects. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paxlovid. Can be co-administered with Caution/monitoring. Abrupt discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paxlovid is discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paxlovid is discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8
Celecoxib Ceritinib Cetirizine Chlordiazepoxide Ciclesonide (inhaled) Cidofovir Cilostazol (50 mg bid) Citalopram Clarithromycin – consult pharmacist Clobazam Clonazepam Clonidine Clopidogrel Clorazepate for anxiety	Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Do not use Paxlovid. Visit https://www.bic.org/for.physicians/covid for alternatives. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Reduce concomitant medication dose, if clinically appropriate and monitor for adverse effects. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paxlovid. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Reduce concomitant medication dose, if clinically appropriate and monitor for adverse effects. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paxlovid. Can be co-administered with caution/monitoring. Abrupt discontinuation or rapid dose reduction
Celecoxib Ceritinib Cetirizine Chlordiazepoxide Ciclesonide (inhaled) Cidofovir Cilostazol (50 mg bid) Citalopram Clarithromycin – consult pharmacist Clobazam Clonazepam Clonidine Clopidogrel Clorazepate for anxiety Clorazepate for seizures	Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with acution/monitoring. Abrupt discontinuation or rapid dose reduction of benzodiazepines may precipitate acute withdrawal reactions. The risk is greatest for patients who have been using higher doses of benzodiazepines over an extended period of time. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paxlovid. Can be co-administered with caution/monitoring. Abrupt discontinuation or rapid dose reduction of benzodiazepines may precipitate acute withdrawal reactions. The risk is greatest for patients who have been using higher doses of benzodiazepines over an extended period of time. Can be co-administered with caution/monitoring. Abrupt discontinuation or rapid dose reduction of ben
Celecoxib Ceritinib Cetirizine Chlordiazepoxide Ciclesonide (inhaled) Cidofovir Cilostazol (50 mg bid) Citalopram Clarithromycin – consult pharmacist Clobazam Clonazepam Clonidine Clopidogrel Clorazepate for anxiety	Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Do not use Paxlovid. Visit https://www.bic.org/for.physicians/covid for alternatives. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Reduce concomitant medication dose, if clinically appropriate and monitor for adverse effects. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paxlovid. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Reduce concomitant medication dose, if clinically appropriate and monitor for adverse effects. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paxlovid. Can be co-administered with caution/monitoring. Abrupt discontinuation or rapid dose reduction
Celecoxib Ceritinib Cetirizine Chlordiazepoxide Ciclesonide (inhaled) Cidofovir Cilostazol (50 mg bid) Citalopram Clarithromycin – consult pharmacist Clobazam Clonazepam Clonidine Clonidine Clopidogrel Clorazepate for anxiety Clorazepate for seizures Clozapine Cobicistat- regimens monitor for increased Paxlovid or	Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Reduce concomitant medication dose, if clinically appropriate and monitor for adverse effects. CVP3A4 inhibition resolves approximately 3 days after Paxlovid. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Reduce concomitant medication dose, if clinically appropriate and monitor for adverse effects. CVP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paxlovid. Can be co-administered with caution/monitoring. Abrupt discontinuation or rapid dose reduction of benzodiazepines may precipitate acute withdrawal reactions. The risk is greatest for patients who have been using higher doses of benzodiazepines over an extended period of time. Can be co-administered with Caution/monitoring. Abrupt discon
Celecoxib Ceritinib Cetirizine Chlordiazepoxide Ciclesonide (inhaled) Cidofovir Cilostazol (50 mg bid) Citalopram Clarithromycin – consult pharmacist Clobazam Clonazepam Clonidine Clonidine Clopidogrel Clorazepate for anxiety Clorazepate for seizures Clozapine Cobicistat- regimens monitor for increased Paxlovid or protease inhibitor adverse	Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with acution/monitoring. Abrupt discontinuation or rapid dose reduction of benzodiazepines may precipitate acute withdrawal reactions. The risk is greatest for patients who have been using higher doses of benzodiazepines over an extended period of time. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paxlovid. Can be co-administered with caution/monitoring. Abrupt discontinuation or rapid dose reduction of benzodiazepines may precipitate acute withdrawal reactions. The risk is greatest for patients who have been using higher doses of benzodiazepines over an extended period of time. Can be co-administered with caution/monitoring. Abrupt discontinuation or rapid dose reduction of ben
Celecoxib Ceritinib Cetirizine Chlordiazepoxide Ciclesonide (inhaled) Cidofovir Cilostazol (50 mg bid) Citalopram Clarithromycin – consult pharmacist Clobazam Clonazepam Clonidine Clonidine Clopidogrel Clorazepate for anxiety Clorazepate for seizures Clozapine Cobicistat- regimens monitor for increased Paxlovid or	Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Reduce concomitant medication dose, if clinically appropriate and monitor for adverse effects. CVP3A4 inhibition resolves approximately 3 days after Paxlovid. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Reduce concomitant medication dose, if clinically appropriate and monitor for adverse effects. CVP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paxlovid. Can be co-administered with caution/monitoring. Abrupt discontinuation or rapid dose reduction of benzodiazepines may precipitate acute withdrawal reactions. The risk is greatest for patients who have been using higher doses of benzodiazepines over an extended period of time. Can be co-administered with Caution/monitoring. Abrupt discon
Celecoxib Ceritinib Cetirizine Chlordiazepoxide Ciclesonide (inhaled) Cidofovir Cilostazol (50 mg bid) Citalopram Clarithromycin – consult pharmacist Clobazam Clonazepam Clonidine Clonidine Clopidogrel Clorazepate for anxiety Clorazepate for seizures Clozapine Cobicistat- regimens monitor for increased Paxlovid or protease inhibitor adverse advents	Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Reduce concomitant medication dose, if clinically appropriate and monitor for adverse effects. CVP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise stated, interaction expected or interaction is of minimal significance given short Paxlovid duration. Reduce concomitant medication dose, if clinically appropriate and monitor for adverse effects. CVP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paxlovid. Can be co-administered with acution/monitoring. Abrupt discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from patients who have bee
Celecoxib Ceritinib Cetirizine Chlordiazepoxide Ciclesonide (inhaled) Cidofovir Cilostazol (50 mg bid) Citalopram Clarithromycin – consult pharmacist Clobazam Clonazepam Clonidine Clopidogrel Clorazepate for anxiety Clorazepate for seizures Clozapine Cobicistat- regimens monitor for increased Paxlovid or protease inhibitor adverse advents Codeine Colchicine Colchicine	Can be co-administered with Paslovid. No interaction expected or interaction is of minimal significance given short Paslovid duration. Can be co-administered with Paslovid. No interaction expected or interaction is of minimal significance given short Paslovid duration. Can be co-administered with calovid. No interaction expected or interaction is of minimal significance given short Paslovid duration. Can be co-administered with calovid. No interaction expected or interaction is of minimal significance given short Paslovid duration. Can be co-administered with calovid. No interaction expected or interaction is of minimal significance given short Paslovid duration. Can be co-administered with Paslovid. No interaction expected or interaction is of minimal significance given short Paslovid duration. Can be co-administered with Paslovid. No interaction expected or interaction is of minimal significance given short Paslovid duration. Can be co-administered with Paslovid. No interaction expected or interaction is of minimal significance given short Paslovid duration. Can be co-administered with Paslovid. No interaction expected or interaction is of minimal significance given short Paslovid duration. Can be co-administered with calovid. No interaction expected or interaction is of minimal significance given short Paslovid duration. Reduce concombinate medication does, if clinically appropriate and montor for adverse effects. CYPAI hinbliton resolves approximately 3 days after Paslovid is discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paslovid. Can be co-administered with cautoin/monitoring. Abrupt discontinuation or rapid dose reduction of benzodiazepines may precipitate acute withdrawal reactions. The risk is greatest for patients who have been using higher doses of benzodiazepines over an extended period of time. Can be co-administered with cautoin/monitoring. Can be co-administered with Paslovid. No interaction expect
Celecoxib Ceritinib Cetirizine Chlordiazepoxide Ciclesonide (inhaled) Cidofovir Cilostazol (50 mg bid) Citalopram Clarithromycin – consult pharmacist Clobazam Clonazepam Clonidine Clonidine Clopidogrel Clorazepate for anxiety Clorazepate for seizures Clozapine Cobicistat- regimens monitor for increased Paxlovid or protease inhibitor adverse advents Codeine Colchicine Corticosteroids (inhaled) Cyclobenzaprine	Can be co-administered with Paslovid. No interaction expected or interaction is of minimal significance given short Paslovid duration. Can be co-administered with Paslovid. No interaction expected or interaction is of minimal significance given short Paslovid duration. Can be co-administered with exalovid. No interaction expected or interaction is of minimal significance given short Paslovid duration. Can be co-administered with exalovid. No interaction expected or interaction is of minimal significance given short Paslovid duration. Can be co-administered with exalovid. No interaction expected or interaction is of minimal significance given short Paslovid duration. Can be co-administered with exalovid. No interaction expected or interaction is of minimal significance given short Paslovid duration. Can be co-administered with Paslovid. No interaction expected or interaction is of minimal significance given short Paslovid duration. Can be co-administered with Paslovid. No interaction expected or interaction is of minimal significance given short Paslovid duration. Can be co-administered with Paslovid. No interaction expected or interaction is of minimal significance given short Paslovid duration. Reduce concomitant medication dose, if clinically appropriate and monitor for adverse effects. CYP3A4 inhibition resolves approximately 3 days after Paslovid is discontinued. Unless otherwise stated, interacting medications should be managed (lose-reduced/extra monitoring) for 8 days from the first dose of Paslovid. Can be co-administered with aution/monitoring. Abrupt discontinuation or rapid dose reduction of benzodiazepines may precipitate acute withdrawal reactions. The risk is greatest for patients who have been using higher doses of benzodiazepines over an extended period of time. Can be co-administered with aution/monitoring. Ca
Celecoxib Ceritinib Cetirizine Chlordiazepoxide Ciclesonide (inhaled) Cidofovir Cilostazol (50 mg bid) Citalopram Clarithromycin – consult pharmacist Clobazam Clonazepam Clonidine Clopidogrel Clorazepate for anxiety Clorazepate for seizures Clozapine Cobicistat- regimens monitor for increased Paxlovid or protease inhibitor adverse advents Codeine Colchicine Colchicine	Can be co-administered with Paslovid. No interaction expected or interaction is of minimal significance given short Paslovid duration. Can be co-administered with Paslovid. No interaction expected or interaction is of minimal significance given short Paslovid duration. Can be co-administered with calovid. No interaction expected or interaction is of minimal significance given short Paslovid duration. Can be co-administered with calovid. No interaction expected or interaction is of minimal significance given short Paslovid duration. Can be co-administered with calovid. No interaction expected or interaction is of minimal significance given short Paslovid duration. Can be co-administered with Paslovid. No interaction expected or interaction is of minimal significance given short Paslovid duration. Can be co-administered with Paslovid. No interaction expected or interaction is of minimal significance given short Paslovid duration. Can be co-administered with Paslovid. No interaction expected or interaction is of minimal significance given short Paslovid duration. Can be co-administered with Paslovid. No interaction expected or interaction is of minimal significance given short Paslovid duration. Can be co-administered with calovid. No interaction expected or interaction is of minimal significance given short Paslovid duration. Reduce concombinate medication does, if clinically appropriate and montor for adverse effects. CYPAI hinbliton resolves approximately 3 days after Paslovid is discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paslovid. Can be co-administered with cautoin/monitoring. Abrupt discontinuation or rapid dose reduction of benzodiazepines may precipitate acute withdrawal reactions. The risk is greatest for patients who have been using higher doses of benzodiazepines over an extended period of time. Can be co-administered with cautoin/monitoring. Can be co-administered with Paslovid. No interaction expect
Celecoxib Ceritinib Cetirizine Chlordiazepoxide Ciclesonide (inhaled) Cidofovir Cilostazol (50 mg bid) Citalopram Clarithromycin – consult pharmacist Clobazam Clonazepam Clonidine Clonidine Clopidogrel Clorazepate for anxiety Clorazepate for seizures Clozapine Cobicistat- regimens monitor for increased Paxlovid or protease inhibitor adverse advents Codeine Colchicine Colchicine Corticosteroids (inhaled) Cyclobenzaprine Cyclosporine - consult	Can be co-administered with Pakovid. No interaction expected or interaction is of minimal significance given short Pakovid duration. Can be co-administered with Pakovid. No interaction expected or interaction is of minimal significance given short Pakovid duration. Can be co-administered with advoid. No interaction expected or interaction is of minimal significance given short Pakovid duration. Can be co-administered with advoid. No interaction expected or interaction is of minimal significance given short Pakovid duration. Can be co-administered with advoid. No interaction expected or interaction is of minimal significance given short Pakovid duration. Can be co-administered with Pakovid. No interaction expected or interaction is of minimal significance given short Pakovid duration. Can be co-administered with Pakovid. No interaction expected or interaction is of minimal significance given short Pakovid duration. Can be co-administered with Pakovid. No interaction expected or interaction is of minimal significance given short Pakovid duration. Can be co-administered with Pakovid. No interaction expected or interaction is of minimal significance given short Pakovid duration. Reduce concentiant medication dose, if clinically appropriate and monitor for adverse effects. CVP3A4 inhibition resolves approximately 3 days after Pakovid is discontinued. Unless otherwise stated, interaction should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Pakovid. Can be co-administered with Pakovid. No interaction of benzodiazepines may precipitate acute withdrawal reactions. The risk is greatest for patients who have been using higher doses of benzodiazepines over an extended period of time. Can be co-administered with Pakovid. No interaction of benzodiazepines may precipitate acute withdrawal reactions. The risk is greatest for patients who have been using higher doses of benzodiazepines over an extended period of time. Can be co-administered with caution/monitoring. Televice diffect
Celecoxib Ceritinib Cetirizine Chlordiazepoxide Ciclesonide (inhaled) Cidofovir Cilostazol (50 mg bid) Citalopram Clarithromycin – consult pharmacist Clobazam Clonazepam Clonidine Clopidogrel Clorazepate for anxiety Clorazepate for seizures Clozapine Cobicistat- regimens monitor for increased Paxlovid or protease inhibitor adverse advents Codeine Colchicine Cocoticosteroids (inhaled) Cyclobenzaprine Cyclosporine - consult pharmacist	Can be co-administered with Paakovid. No interaction expected or interaction is of minimal significance given short Paakovid duration. Can be co-administered with Paakovid. No interaction expected or interaction is of minimal significance given short Paakovid duration. Can be co-administered with aukovid. No interaction expected or interaction is of minimal significance given short Paakovid duration. Can be co-administered with aukovid. No interaction expected or interaction is of minimal significance given short Paakovid duration. Can be co-administered with aukovid. No interaction expected or interaction is of minimal significance given short Paakovid duration. Can be co-administered with Paakovid. No interaction expected or interaction is of minimal significance given short Paakovid duration. Can be co-administered with Paakovid. No interaction expected or interaction is of minimal significance given short Paakovid duration. Can be co-administered with Paakovid. No interaction expected or interaction is of minimal significance given short Paakovid duration. Reduce concomitant medication dose, if clinically appropriate and monitor for adverse effects. CVP344 (hibition resolves approximately 3 days after Paakovid is discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 3 days from the first dose of Paakovid. Can be co-administered with Aukovid. No interaction of benzoalizageines may precipitate acute withdrawal reactions. The risk is greatest for patients who have been using higher doses of benzoalizageines over an extended period of time. Can be co-administered with acution/monitoring. Abrupt discontinuation or rapid dose reduction of benzoalizageines may precipitate acute withdrawal reactions. The risk is greatest for patients who have been using higher doses of benzoalizageines over an extended period of time. Can be co-administered with acution/monitoring. The patient free to a streng developed of time. Can be co-administered w
Celecoxib Ceritinib Cetirizine Chlordiazepoxide Ciclesonide (inhaled) Cidofovir Cilostazol (50 mg bid) Citalopram Clarithromycin – consult pharmacist Clobazam Clonazepam Clonidine Clonidine Clopidogrel Clorazepate for anxiety Clorazepate for seizures Clozapine Cobicistat- regimens monitor for increased Paxlovid or protease inhibitor adverse advents Codeine Colchicine Coclchicine Corticosteroids (inhaled) Cyclobenzaprine Cyclosporine - consult pharmacist Dabigatran - consult pharmacist	Can be co-administered with Paolovid. No interaction expected or interaction is of minimal significance given short Paolovid duration. Date to administered with Paolovid. No interaction expected or interaction is of minimal significance given short Paolovid duration. Can be co-administered with Paolovid. No interaction expected or interaction is of minimal significance given short Paolovid duration. Can be co-administered with autoin/monitoring. Arrupt discontinuation or rapid dose reduction of benzodizepines may precipitate acute withdrawal reactions. The risk is greatest for patients who have been using higher doses of benzodizepines over an exclened period of time. Can be co-administered with Paolovid. No interaction expected or interaction is of minimal significance given short Paolovid duration. Can be co-administered with Paolovid. No interaction expected or interaction is of minimal significance given short Paolovid duration. Can be co-administered with Paolovid. No interaction expected or interaction is of minimal significance given short Paolovid duration. Reduce concentrant medication dose, if clinically appropriate and monitor for adverse effects. CYP3A4 inhibition resolves approximately 3 days after Paolovid is discontinued. Unless otherwise stated, interacting medications should be managed (dose-creduced)exist medications. Can be co-administered with caution/monitoring. Arvupt discontinuation or rapid dose reduction of benzodizepines may precipitate acute withdrawal reactions. The risk is greatest for patients who have been using higher doses of benzodiazepines over an extended period of time. Can be co-administered with acution/monitoring. Arvupt discontinuation or rapid dose reduction of benzodizepines may precipitate acute withdrawal reactions. The risk is greatest for patients who have been using higher doses of benzodiazepines over an extended period of time. Can be co-administered with Paolovid. No interaction expected or interaction is of minimal significance given short Paolovid
Celecoxib Ceritinib Cetirizine Chlordiazepoxide Ciclesonide (inhaled) Cidofovir Cilostazol (50 mg bid) Citalopram Clarithromycin – consult pharmacist Clobazam Clonazepam Clonidine Clopidogrel Clorazepate for anxiety Clorazepate for seizures Clozapine Cobicistat- regimens monitor for increased Paxlovid or protease inhibitor adverse advents Codeine Colchicine Cocoticosteroids (inhaled) Cyclobenzaprine Cyclosporine - consult pharmacist	Can be co-administered with Paskovid. No interaction expected or interaction is of minimal significance given short Paskovid duration. Can be co-administered with Paskovid. No interaction expected or interaction is of minimal significance given short Paskovid duration. Can be co-administered with autoin/monitoring. Arrupt discontinuation or rapid dose reduction of benzodizepines may precipitate acute withdrawal reactions. The risk is greatest for patients who have been using higher doses of benzodizepines over an extended period of time. Can be co-administered with autoid. No interaction expected or interaction is of minimal significance given short Paskovid duration. Can be co-administered with Paskovid. No interaction expected or interaction is of minimal significance given short Paskovid duration. Can be co-administered with Paskovid. No interaction expected or interaction is of minimal significance given short Paskovid duration. Reduce concentrant medication dose, if clinically appropriate and monitor for adverse effects. CYP3A4 inhibition resolves approximately adverse of Paskovid. Can be co-administered with Paskovid. No interaction expected or interaction is of minimal significance given short Paskovid duration. Reduce concentrant medication dose, if clinically appropriate and monitor for adverse effects. CYP3A4 inhibition resolves approximately 3 days after Paskovid is discontinued. Unless otherwes stated, interacting medications should be managed (dose-reduced/xtra monitoring) for 8 days from the first dose of Paskovid. Can be co-administered with acution/monitoring. Anoupt discontinuation or rapid dose reduction of benzodizepines may precipitate acute withdrawal reactions. The risk is greatest for patients who have been using higher doses of benzodizepines over an extended period of time. Can be co-administered with acution/monitoring. Anoupt discontinuation or rapid dose reduction of benzodizepines may precipitate acute withdrawal reactions. The risk is greatest for patients who have
Celecoxib Ceritinib Cetirizine Chlordiazepoxide Ciclesonide (inhaled) Cidofovir Cilostazol (50 mg bid) Citalopram Clarithromycin – consult pharmacist Clobazam Clonazepam Clonazepam Clonidine Clopidogrel Clorazepate for anxiety Clorazepate for seizures Clozapine Clozapine Cobicistat- regimens monitor for increased Paxlovid or protease inhibitor adverse advents Codeine Colchicine Colchicine Colchicine Corticosteroids (inhaled) Cyclobenzaprine Cyclosporine - consult pharmacist Dabigatran - consult pharmacist Dapagliflozin Darifenacin (7.5 mg daily)	Can be co-administered with Paidowid. No interaction expected or interaction is of minimal significance given short Paidowid duration. Dates use Paidowid with Paidowid. No interaction expected or interaction is of minimal significance given short Paidowid duration. Can be co-administered with Paidowid. No interaction expected or interaction is of minimal significance given short Paidowid duration. Can be co-administered with Paidowid. No interaction expected or interaction is of minimal significance given short Paidowid duration. Can be co-administered with Paidowid. No interaction expected or interaction is of minimal significance given short Paidowid duration. Can be co-administered with Paidowid. No interaction expected or interaction is of minimal significance given short Paidowid duration. Can be co-administered with Paidowid. No interaction expected or interaction is of minimal significance given short Paidowid duration. Can be co-administered with Paidowid. No interaction expected or interaction is of minimal significance given short Paidowid duration. Reduce concentrant medication dose, if clinically appropriate and monitor for adverse effects. CVP3A4 inhibition resolves approximately 3 days after Paidowid is discontinued. Unlies otherwise startical, interacting medications should burate effects. CVP3A4 inhibition resolves approximately 3 days after Paidowid is discontinued. Unlies otherwise startical, interacting medications should burate effects. CVP3A4 inhibition resolves approximately 3 days after Paidowid is discontinued. Unlies otherwise startical, interacting medications should burate effects. CVP3A4 inhibition resolves approximately 3 days after Paidowid Is Can be co-administered with Gauton/monitoring. Anyut discontinuation or rapid dos reduction of bencodiazepines may precipitate acute withdrawal reactions. The risk is greatest for patients who have been using higher doses of bencodiazepines over an extended period of time. Can be co-administered with Paidowid. No interaction exp

Dexamethasone (reduce by 50%) Dextromethorphan	Reduce concomitant medication dose, if clinically appropriate and monitor for adverse effects. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paxlovid. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration.
Diazepam	Can be co-administered with caution/monitoring. Abrupt discontinuation or rapid dose reduction of benzodiazepines may precipitate acute withdrawal reactions. The risk is greatest for patients who have been using higher
Digoxin (reduce by 30-50%)	doses of benzodiazepines over an extended period of time. Reduce concomitant medication dose, if clinically appropriate and monitor for adverse effects. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paxlovid.
Dihydroergotamine	Do not use Paxlovid. Visit https://www.bjc.org/for-physicians/covid for alternatives.
Diltiazem (reduce by 50%)	Reduce concomitant medication dose, if clinically appropriate and monitor for adverse effects. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paxlovid.
Diphenhydramine	Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration.
Disopyramide	Do not use Paxlovid. Visit https://www.bjc.org/for-physicians/covid for alternatives.
Dofetilide	Do not use Paxlovid. Visit https://www.bjc.org/for-physicians/covid for alternatives. Temporarily withhold concomitant medications if clinically appropriate. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise
Domperidone	stated, interacting medications should be held for 8 days from the first dose of Paxlovid. Very sensitive or narrow therapeutic index CYP3A4 drugs may need to be held for 10 days after the first dose of Paxlovid.
Donepezil	Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration.
Dronedarone	Do not use Paxlovid. Visit https://www.bjc.org/for-physicians/covid for alternatives.
Dulaglutide Duloxetine	Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration.
Edoxaban (30 mg daily)	Reduce concomitant medication dose, if clinically appropriate and monitor for adverse effects. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is
Eletriptan	discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paxlovid. Temporarily withhold concomitant medications if clinically appropriate. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise stated, interacting medications should be held for 8 days from the first dose of Paxlovid. Very sensitive or narrow therapeutic index CYP3A4 drugs may need to be held for
	10 days after the first dose of Paxlovid
or – consult pharmacist	discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paxlovid. Reduce concomitant medication dose, if clinically appropriate and monitor for adverse effects. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is
Eluxadoline (75 mg bid)	discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paxlovid.
Empagliflozin	Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration.
Enalapril Enoxaparin	Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration.
Enoxaparin Enzalutamide	Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Do not use Paxlovid. Visit https://www.bjc.org/for-physicians/covid for alternatives.
Eplerenone	Do not use Paxlovid. Visit https://www.bjc.org/for-physicians/covid for alternatives.
Eprosartan	Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration.
Ergoloid mesylates	Do not use Paxlovid. Visit https://www.bjc.org/for-physicians/covid for alternatives.
Ergonavine Ergotamine	Do not use Paxlovid. Visit https://www.bjc.org/for-physicians/covid for alternatives.
	Temporarily withhold concomitant medications if clinically appropriate. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise
Erythromycin	stated, interacting medications should be held for 8 days from the first dose of Paxlovid. Very sensitive or narrow therapeutic index CYP3A4 drugs may need to be held for 10 days after the first dose of Paxlovid
Escitalopram Esomeprazole	Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration.
	Temporarily withhold concomitant medications if clinically appropriate. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise
Estazolam	stated, interacting medications should be held for 8 days from the first dose of Paxlovid. Very sensitive or narrow therapeutic index CYP3A4 drugs may need to be held for 10 days after the first dose of Paxlovid. Abrupt discontinuation or rapid dose reduction of benzodiazepines may precipitate acute withdrawal reactions. The risk is greatest for patients who have been using higher doses of benzodiazepines over an extended period of time.
Estrogen-containing	The FDA EUA for ritonavir-boosted nirmatrelvir suggests that individuals who use contraceptive products containing ethinyl estradiol consider using a backup, nonhormonal
contracentives – back-up pop-	contraceptive method because coadministration may result in low ethinyl estradiol levels. However, the low level is not expected to be clinically significant during the 5
Ibormonal mathed required	days of therapy. The progestin concentration of a combined hormonal contraceptive is expected to remain similar or increase with coadministration, which would maintain the effectiveness of the oral contraceptive.
	· · · · · · · · · · · · · · · · · · ·
IEverolimus	Due to severity and unpredictability of interaction, Paxlovid is not recommended. For alternatives visit https://www.bjc.org/for-physicians/covid. If Paxlovid is the only
Everolimus	available option and deemed clinically appropriate, everolimus should be held with therapeutic drug monitoring used to guide re-initiation.
Exenatide	available option and deemed clinically appropriate, everolimus should be held with therapeutic drug monitoring used to guide re-initiation. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration.
	available option and deemed clinically appropriate, everolimus should be held with therapeutic drug monitoring used to guide re-initiation. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration.
Exenatide Ezetimibe Famotidine	available option and deemed clinically appropriate, everolimus should be held with therapeutic drug monitoring used to guide re-initiation. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Reduce concomitant medication dose, if clinically appropriate and monitor for adverse effects. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is
Exenatide Ezetimibe Famotidine Felodipine (reduce by 75%)	available option and deemed clinically appropriate, everolimus should be held with therapeutic drug monitoring used to guide re-initiation. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Reduce concomitant medication dose, if clinically appropriate and monitor for adverse effects. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paxlovid.
Exenatide Ezetimibe Famotidine	available option and deemed clinically appropriate, everolimus should be held with therapeutic drug monitoring used to guide re-initiation. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Reduce concomitant medication dose, if clinically appropriate and monitor for adverse effects. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is
Exenatide Ezetimibe Famotidine Felodipine (reduce by 75%) Fentanyl (reduce by 50%) Fexofenadine	available option and deemed clinically appropriate, everolimus should be held with therapeutic drug monitoring used to guide re-initiation. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Reduce concomitant medication dose, if clinically appropriate and monitor for adverse effects. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paxlovid. Reduce concomitant medication dose, if clinically appropriate and monitor for adverse effects. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paxlovid is discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paxlovid. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration.
Exenatide Ezetimibe Famotidine Felodipine (reduce by 75%) Fentanyl (reduce by 50%)	available option and deemed clinically appropriate, everolimus should be held with therapeutic drug monitoring used to guide re-initiation.Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration.Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration.Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration.Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration.Reduce concomitant medication dose, if clinically appropriate and monitor for adverse effects. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paxlovid.Reduce concomitant medication dose, if clinically appropriate and monitor for adverse effects. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paxlovid.Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration.Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration.Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration.Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid durati
Exenatide Ezetimibe Famotidine Felodipine (reduce by 75%) Fentanyl (reduce by 50%) Fexofenadine	available option and deemed clinically appropriate, everolimus should be held with therapeutic drug monitoring used to guide re-initiation. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Reduce concomitant medication dose, if clinically appropriate and monitor for adverse effects. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paxlovid. Reduce concomitant medication dose, if clinically appropriate and monitor for adverse effects. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paxlovid is discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paxlovid. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration.
Exenatide Ezetimibe Famotidine Felodipine (reduce by 75%) Fentanyl (reduce by 50%) Fexofenadine Finasteride	available option and deemed clinically appropriate, everolimus should be held with therapeutic drug monitoring used to guide re-initiation. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Reduce concomitant medication dose, if clinically appropriate and monitor for adverse effects. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paxlovid. Reduce concomitant medication dose, if clinically appropriate and monitor for adverse effects. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paxlovid. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Temporarily withhold concomitant medications if clinically appropriate. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise stated, interacting medications should be held for 8 days from the first dose of Paxlovid. Very sensitive or narrow therapeutic index CYP3A4 drugs may need to be held for 10 days after the first dose of Paxlovid Do not use Paxlovid . Visit https://www bjc.org/for-physicians/c
Exenatide Ezetimibe Famotidine Felodipine (reduce by 75%) Fentanyl (reduce by 50%) Fexofenadine Finasteride Finerenone	available option and deemed clinically appropriate, everolimus should be held with therapeutic drug monitoring used to guide re-initiation. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Reduce concomitant medication dose, if clinically appropriate and monitor for adverse effects. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paxlovid. Reduce concomitant medication dose, if clinically appropriate and monitor for adverse effects. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paxlovid. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Temporarily withhold concomitant medications if clinically appropriate. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise stated, interacting medications should be held for 8 days from the first dose of Paxlovid. Very sensitive or narrow therapeutic index CYP3A4 drugs may need to be held for 10 days after the first dose of Paxlovid
Exenatide Ezetimibe Famotidine Felodipine (reduce by 75%) Fentanyl (reduce by 50%) Fexofenadine Finasteride Finerenone Flecainide Flibanserin (hold 2 weeks after last Paxlovid dose) Flunisolide (inhaled)	available option and deemed clinically appropriate, everolimus should be held with therapeutic drug monitoring used to guide re-initiation. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Reduce concomitant medication dose, if clinically appropriate and monitor for adverse effects. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paxlovid. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Reduce concomitant medication dose, if clinically appropriate and monitor for adverse effects. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paxlovid. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Temporarily withhold concomitant medicati
Exenatide Ezetimibe Famotidine Felodipine (reduce by 75%) Fentanyl (reduce by 50%) Fexofenadine Finasteride Finerenone Flecainide Flibanserin (hold 2 weeks after last Paxlovid dose) Flunisolide (inhaled) Fluoxetine	available option and deemed clinically appropriate, everolimus should be held with therapeutic drug monitoring used to guide re-initiation. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Reduce concomitant medication dose, if clinically appropriate and monitor for adverse effects. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paxlovid. Reduce concomitant medication dose, if clinically appropriate and monitor for adverse effects. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paxlovid. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction should be dose of Paxlovid. Very sensitive or narrow therapeutic index CYP3A4 drugs may need to be held for 10 days after the first dose of Paxlovid Do not use Paxlovid . Visit https://www.bic.org/for-physicians/covid for alternatives. Temporarily withhold concomitant medications if clinically appropriate. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unle
Exenatide Ezetimibe Famotidine Felodipine (reduce by 75%) Fentanyl (reduce by 50%) Fexofenadine Finasteride Finerenone Flecainide Flibanserin (hold 2 weeks after last Paxlovid dose) Flunisolide (inhaled) Fluoxetine Flurazepam	available option and deemed clinically appropriate, everolimus should be held with therapeutic drug monitoring used to guide re-initiation. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Reduce concomitant medication dose, if clinically appropriate and monitor for adverse effects. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paxlovid. Reduce concomitant medication dose, if clinically appropriate and monitor for adverse effects. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paxlovid. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No
Exenatide Ezetimibe Famotidine Felodipine (reduce by 75%) Fentanyl (reduce by 50%) Fexofenadine Finasteride Finerenone Flecainide Flibanserin (hold 2 weeks after last Paxlovid dose) Flunisolide (inhaled) Fluoxetine	available option and deemed clinically appropriate, everolimus should be held with therapeutic drug monitoring used to guide re-initiation. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Reduce concomitant medication dose, if clinically appropriate and monitor for adverse effects. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paxlovid. Reduce concomitant medication dose, if clinically appropriate and monitor for adverse effects. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paxlovid. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction should be dose of Paxlovid. Very sensitive or narrow therapeutic index CYP3A4 drugs may need to be held for 10 days after the first dose of Paxlovid Do not use Paxlovid . Visit https://www.bic.org/for-physicians/covid for alternatives. Temporarily withhold concomitant medications if clinically appropriate. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unle
Exenatide Ezetimibe Famotidine Felodipine (reduce by 75%) Fentanyl (reduce by 50%) Fexofenadine Finasteride Finerenone Flecainide Flibanserin (hold 2 weeks after last Paxlovid dose) Flunisolide (inhaled) Fluoxetine Flurazepam Fluticasone (inhaled) Formoterol Fosinopril	available option and deemed clinically appropriate, everolimus should be held with therapeutic drug monitoring used to guide re-initiation. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Reduce concomitant medication dose, if clinically appropriate and monitor for adverse effects. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paxlovid. Reduce concomitant medication dose, if clinically appropriate and monitor for adverse effects. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paxlovid. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid is discontinued. Unless otherwise stated, interacting medications should be for 8 days from the first dose of Paxlovid. D days after the first dose of Paxlovid D days after the first dose of Paxlovid Can be co-administered with Paxlovid is discontinued. Unless otherwise stated, interacting medications should be held for 8 days from the first dose of Paxlovid. Very sensitive or narrow therapeutic index CYP3A4 drugs may need to be held for D days after
Exenatide Ezetimibe Famotidine Felodipine (reduce by 75%) Fentanyl (reduce by 50%) Fexofenadine Finasteride Finerenone Flecainide Flibanserin (hold 2 weeks after last Paxlovid dose) Flunisolide (inhaled) Fluoxetine Flurazepam Fluticasone (inhaled) Formoterol Fosinopril Frovatriptan	available option and deemed clinically appropriate, everolimus should be held with therapeutic drug monitoring used to guide re-initiation. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Reduce concomitant medication dose, if clinically appropriate and monitor for adverse effects. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paxlovid. Reduce concomitant medication dose, if clinically appropriate and monitor for adverse effects. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paxlovid. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction ex
Exenatide Ezetimibe Famotidine Felodipine (reduce by 75%) Fentanyl (reduce by 50%) Fexofenadine Finasteride Finerenone Flecainide Flibanserin (hold 2 weeks after last Paxlovid dose) Flunisolide (inhaled) Fluoxetine Flurazepam Fluticasone (inhaled) Formoterol Fosinopril	available option and deemed clinically appropriate, everolimus should be held with therapeutic drug monitoring used to guide re-initiation. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Reduce concomitant medication dose, if clinically appropriate and monitor for adverse effects. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paxlovid. Reduce concomitant medication dose, if clinically appropriate and monitor for adverse effects. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paxlovid. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid is discontinued. Unless otherwise stated, interacting medications should be for 8 days from the first dose of Paxlovid. D days after the first dose of Paxlovid D days after the first dose of Paxlovid Can be co-administered with Paxlovid is discontinued. Unless otherwise stated, interacting medications should be held for 8 days from the first dose of Paxlovid. Very sensitive or narrow therapeutic index CYP3A4 drugs may need to be held for D days after
Exenatide Ezetimibe Famotidine Felodipine (reduce by 75%) Fentanyl (reduce by 50%) Fexofenadine Finasteride Finerenone Filecainide Flibanserin (hold 2 weeks after last Paxlovid dose) Flunisolide (inhaled) Flunzepam Fluticasone (inhaled) Flurazepam Fluticasone (inhaled) Formoterol Fosinopril Frovatriptan Furosemide	available option and deemed clinically appropriate, everolimus should be held with therapeutic drug monitoring used to guide re-initiation. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Reduce concomitant medication dose, if clinically appropriate and monitor for adverse effects. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paxlovid. Reduce concomitant medication dose, if clinically appropriate and monitor for adverse effects. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paxlovid. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Temporarily withhold concomitant medications if clinically appropriate. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise stated, interacting medications should be held for 8 days from the first dose of Paxlovid. Very sensitive or narrow therapeutic index CYP3A4 drugs may need to beheld for 10 days after the first dose of Paxlovid. No interaction is for minimal significance given short Paxlovid is discontinued. Unless otherwise stated, interacting medications should be held for 8 days from the first dose of Paxlovid. Very sensitive or narrow therapeutic index CYP3A4 drugs may need to beheld for 10 days after the first dose of Paxlovid. No interaction expected or
Exenatide Ezetimibe Famotidine Felodipine (reduce by 75%) Fentanyl (reduce by 50%) Fexofenadine Finasteride Finerenone Filecainide Flibanserin (hold 2 weeks after last Paxlovid dose) Flunisolide (inhaled) Flunisolide (inhaled) Flunzepam Fluticasone (inhaled) Formoterol Fosinopril Frovatriptan Furosemide Gabapentin	available option and deemed clinically appropriate, everolimus should be held with therapeutic drug monitoring used to guide re-initiation. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Reduce concomitant medication dose, if clinically appropriate and monitor for adverse effects. CVP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paxlovid. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Temporarily withhold concomitant medications if clinically appropriate. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise stated, interacting medications should be held for 8 days from the first dose of Paxlovid. Very sensitive or narrow therapeutic index CYP3A4 drugs may need to be held for 10 days after the first dose of Paxlovid. Donot use Paxlovid. Visit https://www.bic.org/for.physiclans/cowl for alternatives. Temporarily withhold concomitant medications if clinically appropriate. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless othe
Exenatide Ezetimibe Famotidine Felodipine (reduce by 75%) Fentanyl (reduce by 50%) Fexofenadine Finasteride Finerenone Flecainide Flibanserin (hold 2 weeks after last Paxlovid dose) Flunisolide (inhaled) Fluoxetine Flurazepam Fluticasone (inhaled) Formoterol Fosinopril Frovatriptan Furosemide Gabapentin Glecaprevir/pibrentasvir Hydrocodone (reduce by 50%)	available option and deemed clinically appropriate, everolimus should be held with therapeutic drug monitoring used to guide re-initiation. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Reduce concomitant medication dose, if clinically appropriate and monitor for adverse effects. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paxlovid. Reduce concomitant medication dose, if clinically appropriate and monitor for adverse effects. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise stated, interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is
Exenatide Ezetimibe Famotidine Felodipine (reduce by 75%) Fentanyl (reduce by 50%) Fexofenadine Finasteride Finerenone Flecainide Flibanserin (hold 2 weeks after last Paxlovid dose) Flunisolide (inhaled) Fluoxetine Flurazepam Fluticasone (inhaled) Formoterol Fosinopril Frovatriptan Furosemide Gabapentin Glecaprevir/pibrentasvir Hydrocodone (reduce by 50%) Hydroxychloroquine	available option and deemed clinically appropriate, everolimus should be held with therapeutic drug monitoring used to guide re-initiation. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Reduce concomitant medication dose, if clinically appropriate and monitor for adverse effects. CVP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paxlovid. Reduce concomitant medication dose, if clinically appropriate and monitor for adverse effects. CVP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paxlovid. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Temporarily withhold concomitant medications if clinically appropriate. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise stated, interacting medications should be held for 8 days from the first dose of Paxlovid. Very sensitive or narrow therapeutic index CYP3A4 drugs may need to be held for 10 days after the first dose of Paxlovid. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction i
ExenatideEzetimibeFamotidineFamotidine (reduce by 75%)Fentanyl (reduce by 50%)FexofenadineFinasterideFinerenoneFlecainideFlibanserin (hold 2 weeks after last Paxlovid dose)Flunisolide (inhaled)FluzepamFluticasone (inhaled)FormoterolFosinoprilFrovatriptanFurosemideGabapentinGlecaprevir/pibrentasvirHydrocodone (reduce by 50%)Hydroxyzine	available option and deemed clinically appropriate, everolimus should be held with thrapeutic drug monitoring used to guide re-initiation. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Reduce concomitant medication dose, if clinically appropriate and monitor for adverse effects. CYP3A4 linibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paxlovid. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction explexes approximately 3 days after Paxlovid is discontinued. Unless otherwise stated, interacting medications should be held for 8 days from the first dose of Paxlovid. Very sensitive or narrow therapeutic index CVP3A4 drugs may need to be held for 10 days after the first dose of Paxlovid. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can b
Exenatide Ezetimibe Famotidine Felodipine (reduce by 75%) Fentanyl (reduce by 50%) Fexofenadine Finasteride Finerenone Flecainide Flibanserin (hold 2 weeks after last Paxlovid dose) Flunisolide (inhaled) Fluoxetine Flurazepam Fluticasone (inhaled) Formoterol Fosinopril Frovatriptan Furosemide Gabapentin Glecaprevir/pibrentasvir Hydrocodone (reduce by 50%) Hydroxychloroquine	available option and deemed clinically appropriate, everolimus should be held with therapeutic drug monitoring used to guide re-initiation. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Reduce concomitant medication dose, if clinically appropriate and monitor for adverse effects. CVP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paxlovid. Reduce concomitant medication dose, if clinically appropriate and monitor for adverse effects. CVP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise stated, interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Temporarily withhold concomitant medications if clinically appropriate. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise stated, interacting medications should be held for 8 days from the first dose of Paxlovid. Very sensitive or narrow therapeutic index CYP3A4 drugs may need to be held for 10 days after the first dose of Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can b
Exenatide Ezetimibe Famotidine Felodipine (reduce by 75%) Fentanyl (reduce by 50%) Fexofenadine Finasteride Finasteride Finerenone Flecainide Flibanserin (hold 2 weeks after last Paxlovid dose) Flunisolide (inhaled) Fluoxetine Flurazepam Fluticasone (inhaled) Formoterol Formoterol Fosinopril Frovatriptan Furosemide Gabapentin Glecaprevir/pibrentasvir Hydrocodone (reduce by 50%) Hydroxyzine Ibrutinib Ibuprofen	available option and deemed dinically appropriate, everolimus should be held with therapeutic drug monitoring used to guide re-initiation. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Reduce concomitant medication dose, if clinically appropriate and monitor for adverse effects. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise stated, interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Temporarily withhold concomitant medications if clinically appropriate. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise stated, interacting medications should be held for 8 days from the first dose of Paxlovid. Very sensitive or narrow therapeutic index CYP3A4 drugs may need to be held for days after the first dose of Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expe
Exenatide Ezetimibe Famotidine Felodipine (reduce by 75%) Fentanyl (reduce by 50%) Fexofenadine Finasteride Finerenone Filecainide Flibanserin (hold 2 weeks after last Paxlovid dose) Flunisolide (inhaled) Fluoxetine Flurazepam Fluticasone (inhaled) Formoterol Fosinopril Frovatriptan Furosemide Gabapentin Glecaprevir/pibrentasvir Hydrocodone (reduce by 50%) Hydroxyzine Ibrutinib Ibuprofen Iloperidone (reduce by 50%)	available option and deemed clinically appropriate, everolimus should be held with therapeutic drug monitoring used to guide re-initiation. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Reduce concombant medication dese, If clinically appropriate and monitor for adverse effects. CPP34 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise stated, interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or alteraction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or alteration is of mainimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or alternative. Temporarily withhold concomitant medications if clinically appropriate. CPP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise stated, interacting medications should be held for 8 days from the first dose of Paxlovid. Very sensitive or narrow therapeutic index CPP3A4 drugs may need to be held for 10 days after the first dose of Paxlovid. No interaction expected or interaction is of minimal significance given sh
Exenatide Ezetimibe Famotidine Felodipine (reduce by 75%) Fentanyl (reduce by 50%) Fexofenadine Finasteride Finasteride Finerenone Flecainide Flibanserin (hold 2 weeks after last Paxlovid dose) Flunisolide (inhaled) Fluoxetine Flurazepam Fluticasone (inhaled) Formoterol Formoterol Fosinopril Frovatriptan Furosemide Gabapentin Glecaprevir/pibrentasvir Hydrocodone (reduce by 50%) Hydroxyzine Ibrutinib Ibuprofen	available option and deemed dinically appropriate, everolimus should be held with therapeutic drug monitoring used to guide re-initiation. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Reduce concomitant medication dose, if clinically appropriate and monitor for adverse effects. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise stated, interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Temporarily withhold concomitant medications if clinically appropriate. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise stated, interacting medications should be held for 8 days from the first dose of Paxlovid. Very sensitive or narrow therapeutic index CYP3A4 drugs may need to be held for days after the first dose of Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expe
ExenatideEzetimibeFamotidineFamotidineFelodipine (reduce by 75%)Fentanyl (reduce by 50%)FexofenadineFinasterideFinerenoneFlecainideFlibanserin (hold 2 weeks after last Paxlovid dose)Flunisolide (inhaled)FluxetineFlurazepamFluticasone (inhaled)FormoterolFosinoprilFrovatriptanFurosemideGabapentinGlecaprevir/pibrentasvirHydrocodone (reduce by 50%)HydroxyzineIbrutinibIbuprofenIloperidone (reduce by 50%)Insulin	available option and deemed clinically appropriate, everolinus should be held with therapeutic drug monitoring used to guide re-initiation. Can be co-administered with Paxiovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Reduce concombinat medication does, if clinically appropriate and monitor for adverse effects. CP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise stated, interacting propriate and monitor for adverse effects. CP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise stated, interaction sepected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance
ExenatideEzetimibeFamotidineFamotidine (reduce by 75%)Fentanyl (reduce by 50%)FexofenadineFinasterideFinerenoneFlecainideFlibanserin (hold 2 weeks after last Paxlovid dose)Flunisolide (inhaled)FluzazepamFluticasone (inhaled)FormoterolFosinoprilFrovatriptanFurosemideGabapentinGlecaprevir/pibrentasvirHydrocodone (reduce by 50%)HydroxyzineIburinibIbuprofenIloperidone (reduce by 50%)InsulinIrbesartanIsosorbide DinitrateItraconazole (max 200	available option and deemed clinically appropriate, everolinus should be held with therapeutic drug monitoring used to guide re-initiation. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction schould be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paxlovid is discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paxlovid. Can be co-administered with Paxlovid. No interaction cox exceted or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interacticon expected or interaction is of minimal significance given short Paxlovid duration. Temporarity withhold concentratin mediciations if clinically appropriate. CYP34 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise stated, interacting medications should be held for 8 days from the first dose of Paxlovid. Very sensitive or narrow therapeutic index CYP34A drugs may need to be held for 10 days after the first dose of Paxlovid. We interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expect
ExenatideEzetimibeFamotidineFamotidine (reduce by 75%)Fentanyl (reduce by 50%)FexofenadineFinasterideFinerenoneFlecainideFlibanserin (hold 2 weeks after last Paxlovid dose)Flunisolide (inhaled)FluzazepamFluticasone (inhaled)FormoterolFosinoprilFrovatriptanFurosemideGabapentinGlecaprevir/pibrentasvirHydrocodone (reduce by 50%)HydroxyzineIburtinibIbuprofenIloperidone (reduce by 50%)InsulinIrbesartanIsosorbide DinitrateItraconazole (max 200mg/day)	available option and deemed clinically appropriate, everolimus should be held with therapeutic drug monitoring used builder e-initiation. Can be co-administered with Pakovid. No interaction expected or interaction is of minimal significance given short Pakovid duration. Can be co-administered with Pakovid. No interaction expected or interaction is of minimal significance given short Pakovid duration. Can be co-administered with Pakovid. No interaction expected or interaction is of minimal significance given short Pakovid a duration. Can be co-administered with Pakovid. No interaction expected or interaction is of minimal significance given short Pakovid a state. Meduce concomitant medication does, if clinically appropriate and monitor for adverse effects. CPP34 Inhibition resolves approximately 3 days after Pakovid is discontinued. Unless otherwise stated, interaction expected or interaction is of minimal significance given short Pakovid is discontinued. Unless otherwise stated, interaction expected or interaction is of minimal significance given short Pakovid is discontinued. Unless otherwise stated, interaction expected or interaction is of minimal significance given short Pakovid is discontinued. Unless otherwise espected and the days from the first dose of Pakovid. Can be co-administered with Pakovid. No interaction expected or interaction is of minimal significance given short Pakovid is discontinued. Unless otherwise stated, interactive divers should be held for 8 days from the first dose of Pakovid. Very sansitive or narrow therapeutic index CPP3A drugs may need to be held for 8 days from the first dose of Pakovid. Can be co-administered with Pakovid. No interaction expected or interaction is of minimal significance given short Pakovid is discontinued. Unless otherwise state, interactive divers david. No interaction expected or interaction is of minimal significance given short Pakovid duration. Can be co-administered with Pakovid. No interaction expected or interaction is of minimal significance given s
ExenatideEzetimibeFamotidineFamotidineFelodipine (reduce by 75%)Fentanyl (reduce by 50%)FexofenadineFinasterideFinerenoneFlecainideFlibanserin (hold 2 weeks after last Paxlovid dose)Flunisolide (inhaled)FluxetineFlurazepamFluticasone (inhaled)FormoterolFosinoprilFrovatriptanFurosemideGabapentinGlecaprevir/pibrentasvirHydrocodone (reduce by 50%)HydroxyzineIbrutinibIbuprofenIloperidone (reduce by 50%)InsulinIrbesartanIsosorbide DinitrateItraconazole (max 200mg/day)Ivabradine	available option and deemed clinically appropriate, everolimus should be held with therapeutic drug monitoring used build existination. Can be co-administered with Padovid. No interaction expected or interaction is of minimal significance given short Pavlovid duration. Can be co-administered with Padovid. No interaction expected or interaction is of minimal significance given short Pavlovid duration. Can be co-administered with Padovid. No interaction expected or interaction is of minimal significance given short Pavlovid duration. Reduce concomitant medication dose, if clinically appropriate and monitor for adverse effects. CPF344 hinbition resolves approximately 3 days after Padovid is discontinued. Unless otherwise stated, interacting medications should be managed (dose reduced/exit monitoring) for 8 days from the first dose of Padovid. Can be co-administered with Padovid. No interaction expected or interaction is of minimal significance given short Padovid duration. Can be co-administered with Padovid. No interaction expected or interaction is of minimal significance given short Padovid duration. Can be co-administered with Padovid. No interaction expected or interaction is of minimal significance given short Padovid duration. Can be co-administered with Padovid. No interaction expected or interaction is of minimal significance given short Padovid duration. Can be co-administered with Padovid. No interaction expected or interaction is of minimal significance given short Padovid duration. Can be co-administered with Padovid. No interaction expected or interaction is of minimal significance given short Padovid duration. Can be co-administered with Padovid. No interaction expected or interaction is of minimal significance given short Padovid duration. Can be co-administered with Padovid. No interaction expected or interaction is of minimal significance given short Padovid duration. Can be co-administered with Padovid. No interaction expected or interaction is of minimal significance given short P
ExenatideEzetimibeFamotidineFamotidine (reduce by 75%)Fentanyl (reduce by 50%)FexofenadineFinasterideFinerenoneFlecainideFlibanserin (hold 2 weeks after last Paxlovid dose)Flunisolide (inhaled)FluzazepamFluticasone (inhaled)FormoterolFosinoprilFrovatriptanFurosemideGabapentinGlecaprevir/pibrentasvirHydrocodone (reduce by 50%)HydroxyzineIburtinibIbuprofenIloperidone (reduce by 50%)InsulinIrbesartanIsosorbide DinitrateItraconazole (max 200mg/day)	available option and deemed clinically appropriate, everolimus should be held with therapeutic drug monitoring used build existination. Can be co-administered with Padovid. No interaction expected or interaction is of minimal significance given short Pavlovid duration. Can be co-administered with Padovid. No interaction expected or interaction is of minimal significance given short Pavlovid duration. Can be co-administered with Padovid. No interaction expected or interaction is of minimal significance given short Pavlovid duration. Reduce concomitant medication dose, if clinically appropriate and monitor for adverse effects. CPF344 hinbition resolves approximately 3 days after Padovid is discontinued. Unless otherwise stated, interacting medications should be managed (dose reduced/exit monitoring) for 8 days from the first dose of Padovid. Can be co-administered with Padovid. No interaction expected or interaction is of minimal significance given short Padovid duration. Can be co-administered with Padovid. No interaction expected or interaction is of minimal significance given short Padovid duration. Can be co-administered with Padovid. No interaction expected or interaction is of minimal significance given short Padovid duration. Can be co-administered with Padovid. No interaction expected or interaction is of minimal significance given short Padovid duration. Can be co-administered with Padovid. No interaction expected or interaction is of minimal significance given short Padovid duration. Can be co-administered with Padovid. No interaction expected or interaction is of minimal significance given short Padovid duration. Can be co-administered with Padovid. No interaction expected or interaction is of minimal significance given short Padovid duration. Can be co-administered with Padovid. No interaction expected or interaction is of minimal significance given short Padovid duration. Can be co-administered with Padovid. No interaction expected or interaction is of minimal significance given short P

Ketoconazole (max 200	Reduce concomitant medication dose, if clinically appropriate and monitor for adverse effects. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is
mg/day)	discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paxlovid.
Labetalol	Can be co-administered with caution/monitoring.
	Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration.
Lansoprazole	
Levothyroxine	Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration.
Lisinopril	Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration.
Lomitapide	Do not use Paxlovid. Visit https://www.bjc.org/for-physicians/covid for alternatives.
Lonafarnib	Do not use Paxlovid. Visit https://www.bjc.org/for-physicians/covid for alternatives.
Loratadine	Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration.
Lorazepam	Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration.
Losartan	Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration.
	Temporarily withhold concomitant medications if clinically appropriate. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise
Lovastatin	stated, interacting medications should be held for 8 days from the first dose of Paxlovid. Very sensitive or narrow therapeutic index CYP3A4 drugs may need to be held for
	10 days after the first dose of Paxlovid
Lumacaftor/ivacaftor	Do not use Paxlovid. Visit https://www.bjc.org/for-physicians/covid for alternatives.
	Do not use Paxlovid. Visit https://www.bjc.org/for-physicians/covid for alternatives.
Lumateperone	
Lurasidone	Do not use Paxlovid. Visit https://www.bjc.org/for-physicians/covid for alternatives.
Macitentan	Do not use Paxlovid. Visit https://www.bjc.org/for-physicians/covid for alternatives.
Maraviroc – consult	Reduce concomitant medication dose, if clinically appropriate and monitor for adverse effects. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is
pharmacist	discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paxlovid.
Meloxicam	Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration.
Meperidine	Do not use Paxlovid. Visit https://www.bjc.org/for-physicians/covid for alternatives.
Metformin	Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration.
Methadone – monitor for	can be do administered with raxiovid duration.
	Can be co-administered with caution/monitoring.
withdrawal	
Methotrexate	Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration.
Methylergonovine	Do not use Paxlovid. Visit https://www.bjc.org/for-physicians/covid for alternatives.
Methylprednisolone	Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration.
Metoprolol	Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration.
Mexiletine	Do not use Paxlovid. Visit https://www.bjc.org/for-physicians/covid for alternatives.
Midazolam - oral	Do not use Paxlovid. Visit https://www.bjc.org/for-physicians/covid for alternatives.
Mometasone (inhaled)	Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration.
Montelukast	Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration.
Mycophenolate	Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration.
	Temporarily withhold concomitant medications if clinically appropriate. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise
Naloxegol	stated, interacting medications should be held for 8 days from the first dose of Paxlovid. Very sensitive or narrow therapeutic index CYP3A4 drugs may need to be held for
	10 days after the first dose of Paxlovid
Naproxen	Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration.
Naratriptan	Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration.
Neratinib	Do not use Paxlovid. Visit https://www.bjc.org/for-physicians/covid for alternatives.
	Temporarily withhold concomitant medications if clinically appropriate. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise
Nicardipine (reduce by 50%)	stated, interacting medications should be held for 8 days from the first dose of Paxlovid. Very sensitive or narrow therapeutic index CYP3A4 drugs may need to be held for
(reduce by 50%)	10 days after the first dose of Paxlovid
	Temporarily withhold concomitant medications if clinically appropriate. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise
Nifedining (reduce by EO%)	
Nifedipine (reduce by 50%)	stated, interacting medications should be held for 8 days from the first dose of Paxlovid. Very sensitive or narrow therapeutic index CYP3A4 drugs may need to be held for
	10 days after the first dose of Paxlovid
Nilotinib	Do not use Paxlovid. Visit https://www.bjc.org/for-physicians/covid for alternatives.
Nortriptyline	Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration.
Olanzapine	Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration.
Olmesartan	Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration.
Omeprazole	Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration.
Ondansetron	Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration.
	Reduce concomitant medication dose, if clinically appropriate and monitor for adverse effects. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is
Oxycodone (reduce by 75%)	
· · · · · · · · · · · · · · · · · · ·	
	discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paxlovid.
Pantoprazole	discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paxlovid. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration.
Pantoprazole Paroxetine	discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paxlovid. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration.
Pantoprazole Paroxetine Phenobarbital	discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paxlovid. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Do not use Paxlovid. Visit https://www.bjc.org/for-physicians/covid for alternatives.
Pantoprazole Paroxetine	discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paxlovid. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Do not use Paxlovid. Visit https://www.bjc.org/for-physicians/covid for alternatives. Do not use Paxlovid. Visit https://www.bjc.org/for-physicians/covid for alternatives.
Pantoprazole Paroxetine Phenobarbital Phenytoin	discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paxlovid. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Do not use Paxlovid. Visit https://www.bjc.org/for-physicians/covid for alternatives. Do not use Paxlovid. Visit https://www.bjc.org/for-physicians/covid for alternatives. Temporarily withhold concomitant medications if clinically appropriate. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise
Pantoprazole Paroxetine Phenobarbital	discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paxlovid. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Do not use Paxlovid. Visit https://www.bjc.org/for-physicians/covid for alternatives. Do not use Paxlovid. Visit https://www.bjc.org/for-physicians/covid for alternatives. Temporarily withhold concomitant medications if clinically appropriate. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise stated, interacting medications should be held for 8 days from the first dose of Paxlovid. Very sensitive or narrow therapeutic index CYP3A4 drugs may need to be held for
Pantoprazole Paroxetine Phenobarbital Phenytoin Pimavanserin	discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paxlovid. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Do not use Paxlovid. Visit https://www.bjc.org/for-physicians/covid for alternatives. Do not use Paxlovid. Visit https://www.bjc.org/for-physicians/covid for alternatives. Temporarily withhold concomitant medications if clinically appropriate. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise stated, interacting medications should be held for 8 days from the first dose of Paxlovid. Very sensitive or narrow therapeutic index CYP3A4 drugs may need to be held for 10 days after the first dose of Paxlovid
Pantoprazole Paroxetine Phenobarbital Phenytoin	discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paxlovid. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Do not use Paxlovid. Visit https://www.bjc.org/for-physicians/covid for alternatives. Do not use Paxlovid. Visit https://www.bjc.org/for-physicians/covid for alternatives. Temporarily withhold concomitant medications if clinically appropriate. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise stated, interacting medications should be held for 8 days from the first dose of Paxlovid. Very sensitive or narrow therapeutic index CYP3A4 drugs may need to be held for
Pantoprazole Paroxetine Phenobarbital Phenytoin Pimavanserin	discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paxlovid. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Do not use Paxlovid. Visit https://www.bjc.org/for-physicians/covid for alternatives. Do not use Paxlovid. Visit https://www.bjc.org/for-physicians/covid for alternatives. Temporarily withhold concomitant medications if clinically appropriate. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise stated, interacting medications should be held for 8 days from the first dose of Paxlovid. Very sensitive or narrow therapeutic index CYP3A4 drugs may need to be held for 10 days after the first dose of Paxlovid
Pantoprazole Paroxetine Phenobarbital Phenytoin Pimavanserin Pimozide	discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paxlovid.Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration.Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration.Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration.Do not use Paxlovid. Visit https://www.bjc.org/for-physicians/covid for alternatives.Do not use Paxlovid. Visit https://www.bjc.org/for-physicians/covid for alternatives.Temporarily withhold concomitant medications if clinically appropriate. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise stated, interacting medications should be held for 8 days from the first dose of Paxlovid. Very sensitive or narrow therapeutic index CYP3A4 drugs may need to be held for 10 days after the first dose of Paxlovid.Do not use Paxlovid. Visit https://www.bjc.org/for-physicians/covid for alternatives.Do not use Paxlovid. Visit https://www.bjc.org/for-physicians/covid for alternatives.
Pantoprazole Paroxetine Phenobarbital Phenytoin Pimavanserin Pimozide Pioglitazone	discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paxlovid. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Do not use Paxlovid. Visit https://www.bic.org/for-physicians/covid for alternatives. Do not use Paxlovid. Visit https://www.bic.org/for-physicians/covid for alternatives. Temporarily withhold concomitant medications if clinically appropriate. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise stated, interacting medications should be held for 8 days from the first dose of Paxlovid. Very sensitive or narrow therapeutic index CYP3A4 drugs may need to be held for 10 days after the first dose of Paxlovid Do not use Paxlovid. Visit https://www.bic.org/for-physicians/covid for alternatives. Do not use Paxlovid. Visit https://www.bic.org/for-physicians/covid for alternatives. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration.
Pantoprazole Paroxetine Phenobarbital Phenytoin Pimavanserin Pimozide Pioglitazone Pitavastatin Potassium	discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paxlovid. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Do not use Paxlovid. Visit https://www.bic.org/for-physicians/covid for alternatives. Do not use Paxlovid. Visit https://www.bic.org/for-physicians/covid for alternatives. Temporarily withhold concomitant medications if clinically appropriate. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise stated, interacting medications should be held for 8 days from the first dose of Paxlovid. Very sensitive or narrow therapeutic index CYP3A4 drugs may need to be held for 10 days after the first dose of Paxlovid. Visit https://www.bic.org/for-physicians/covid for alternatives. Do not use Paxlovid. Visit https://www.bic.org/for-physicians/covid for alternatives. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration.
Pantoprazole Paroxetine Phenobarbital Phenytoin Pimavanserin Pimozide Pioglitazone Pitavastatin Potassium Prasugrel	discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paxlovid. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Do not use Paxlovid. Visit https://www.bic.org/for-physicians/covid for alternatives. Do not use Paxlovid. Visit https://www.bic.org/for-physicians/covid for alternatives. Temporarily withhold concomitant medications if clinically appropriate. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise stated, interacting medications should be held for 8 days from the first dose of Paxlovid. Very sensitive or narrow therapeutic index CYP3A4 drugs may need to be held for 10 days after the first dose of Paxlovid. Do not use Paxlovid. Visit https://www.bic.org/for-physicians/covid for alternatives. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration.
Pantoprazole Paroxetine Phenobarbital Phenytoin Pimavanserin Pimozide Pioglitazone Pitavastatin Potassium Prasugrel Pravastatin	discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paxlovid. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Do not use Paxlovid. Visit https://www.bjc.org/for-physicians/covid for alternatives. Do not use Paxlovid. Visit https://www.bjc.org/for-physicians/covid for alternatives. Temporarily withhold concomitant medications if clinically appropriate. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise stated, interacting medications should be held for 8 days from the first dose of Paxlovid. Very sensitive or narrow therapeutic index CYP3A4 drugs may need to be held for 10 days after the first dose of Paxlovid Do not use Paxlovid. Visit https://www.bjc.org/for-physicians/covid for alternatives. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovi
Pantoprazole Paroxetine Phenobarbital Phenytoin Pimavanserin Pimozide Pioglitazone Pitavastatin Potassium Prasugrel Pravastatin Prednisolone	discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paxlovid. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Do not use Paxlovid. Visit https://www.bjc.org/for-physicians/covid for alternatives. Do not use Paxlovid. Visit https://www.bjc.org/for-physicians/covid for alternatives. Temporarily withhold concomitant medications if clinically appropriate. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise stated, interacting medications should be held for 8 days from the first dose of Paxlovid. Very sensitive or narrow therapeutic index CYP3A4 drugs may need to be held for 10 days after the first dose of Paxlovid Do not use Paxlovid. Visit https://www.bjc.org/for-physicians/covid for alternatives. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovi
Pantoprazole Paroxetine Phenobarbital Phenytoin Pimavanserin Pimozide Pioglitazone Pitavastatin Potassium Prasugrel Pravastatin Prednisolone Prednisone	discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paxlovid. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Do not use Paxlovid. Visit https://www.bjc.org/for-physicians/covid for alternatives. Do not use Paxlovid. Visit https://www.bjc.org/for-physicians/covid for alternatives. Temporarily withhold concomitant medications if clinically appropriate. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise stated, interacting medications should be held for 8 days from the first dose of Paxlovid. Very sensitive or narrow therapeutic index CYP3A4 drugs may need to be held for 10 days after the first dose of Paxlovid Do not use Paxlovid. Visit https://www.bjc.org/for-physicians/covid for alternatives. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovi
Pantoprazole Paroxetine Phenobarbital Phenytoin Pimavanserin Pimozide Pioglitazone Pitavastatin Potassium Prasugrel Pravastatin Prednisolone Prednisone Primidone	discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paxlovid. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Do not use Paxlovid. Visit https://www.bjc.org/for-physicians/covid for alternatives. Do not use Paxlovid. Visit https://www.bjc.org/for-physicians/covid for alternatives. Do not use Paxlovid. Visit https://www.bjc.org/for-physicians/covid for alternatives. Temporarily withhold concomitant medications if clinically appropriate. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise stated, interacting medications should be held for 8 days from the first dose of Paxlovid. Very sensitive or narrow therapeutic index CYP3A4 drugs may need to be held for 10 days after the first dose of Paxlovid Do not use Paxlovid. Visit https://www.bjc.org/for-physicians/covid for alternatives. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of m
Pantoprazole Paroxetine Phenobarbital Phenytoin Pimavanserin Pimozide Pioglitazone Pitavastatin Potassium Prasugrel Pravastatin Prednisolone Prednisone	discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paxlovid. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Do not use Paxlovid. Visit https://www.bic.org/for-physicians/covid for alternatives. Do not use Paxlovid. Visit https://www.bic.org/for-physicians/covid for alternatives. Do not use Paxlovid. Visit https://www.bic.org/for-physicians/covid for alternatives. Temporarily withhold concomitant medications if clinically appropriate. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise stated, interacting medications should be held for 8 days from the first dose of Paxlovid. Very sensitive or narrow therapeutic index CYP3A4 drugs may need to be held for 10 days after the first dose of Paxlovid Do not use Paxlovid. Noi Interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interactio
Pantoprazole Paroxetine Phenobarbital Phenytoin Pimavanserin Pimozide Pioglitazone Pitavastatin Potassium Prasugrel Pravastatin Prednisolone Prednisone Primidone Propafenone	discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paxlovid. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Do not use Paxlovid. Visit https://www.bjc.org/for-physicians/covid for alternatives. Do not use Paxlovid. Visit https://www.bjc.org/for-physicians/covid for alternatives. Do not use Paxlovid. Visit https://www.bjc.org/for-physicians/covid for alternatives. Temporarily withhold concomitant medications if clinically appropriate. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise stated, interacting medications should be held for 8 days from the first dose of Paxlovid. Very sensitive or narrow therapeutic index CYP3A4 drugs may need to be held for 10 days after the first dose of Paxlovid Do not use Paxlovid. Visit https://www.bjc.org/for-physicians/covid for alternatives. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of m
Pantoprazole Paroxetine Phenobarbital Phenytoin Pimavanserin Pimozide Pioglitazone Pitavastatin Potassium Prasugrel Pravastatin Prednisolone Prednisone Primidone	discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paxlovid. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Do not use Paxlovid. Visit https://www.bic.org/for-physicians/covid for alternatives. Do not use Paxlovid. Visit https://www.bic.org/for-physicians/covid for alternatives. De not use Paxlovid. Visit https://www.bic.org/for-physicians/covid for alternatives. Temporarily withhold concomitant medications if clinically appropriate. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise stated, interacting medications should be held for 8 days from the first dose of Paxlovid. Very sensitive or narrow therapeutic index CYP3A4 drugs may need to be held for 10 days after the first dose of Paxlovid. Do not use Paxlovid. Visit https://www.bic.org/for-physicians/covid for alternatives. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of
Pantoprazole Paroxetine Phenobarbital Phenytoin Pimavanserin Pimozide Pioglitazone Pitavastatin Potassium Prasugrel Pravastatin Prednisolone Prednisone Primidone Propafenone	discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paxlovid. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Do not use Paxlovid. Visit https://www.bic.org/for-physicians/covid for alternatives. Do not use Paxlovid. Visit https://www.bic.org/for-physicians/covid for alternatives. Temporarily withhold concomitant medications if clinically appropriate. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise stated, interacting medications should be held for 8 days from the first dose of Paxlovid. Very sensitive or narrow therapeutic index CYP3A4 drugs may need to be held for 10 days after the first dose of Paxlovid Do not use Paxlovid. Visit https://www.bic.org/for-physiclans/covid for alternatives. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovi
Pantoprazole Paroxetine Phenobarbital Phenytoin Pimavanserin Pimozide Pioglitazone Pitavastatin Potassium Prasugrel Pravastatin Prednisolone Prednisone Primidone Propafenone Quetiapine (reduce by 80%)	discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paxlovid. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Do not use Paxlovid. Visit https://www.bic.org/for-physicians/covid for alternatives. Do not use Paxlovid. Visit https://www.bic.org/for-physicians/covid for alternatives. De not use Paxlovid. Visit https://www.bic.org/for-physicians/covid for alternatives. Temporarily withhold concomitant medications if clinically appropriate. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise stated, interacting medications should be held for 8 days from the first dose of Paxlovid. Very sensitive or narrow therapeutic index CYP3A4 drugs may need to be held for 10 days after the first dose of Paxlovid. Do not use Paxlovid. Visit https://www.bic.org/for-physicians/covid for alternatives. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of
Pantoprazole Paroxetine Phenobarbital Phenytoin Pimavanserin Pimozide Pioglitazone Pitavastatin Potassium Prasugrel Pravastatin Prednisolone Prednisone Primidone Propafenone Quetiapine (reduce by 80%) Quinapril	discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paxlovid. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Do not use Paxlovid. Visit https://www.bjc.org/for-physicians/covid for alternatives. Temporarily withhold concomitant medications if clinically appropriate. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise stated, interacting medications should be held for 8 days from the first dose of Paxlovid. Very sensitive or narrow therapeutic index CYP3A4 drugs may need to be held for 10 days after the first dose of Paxlovid Do not use Paxlovid. Visit https://www.bjc.org/for-physicians/covid for alternatives. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlo
Pantoprazole Paroxetine Phenobarbital Phenytoin Pimavanserin Pimozide Pioglitazone Pitavastatin Potassium Prasugrel Pravastatin Prednisolone Prednisone Primidone Propafenone Quetiapine (reduce by 80%) Quinapril Quinidine Ramipril	discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paxlovid. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Do not use Paxlovid. Visit https://www.bic.org/fo-physicians/covid for alternatives. Be not use Paxlovid. Visit https://www.bic.org/fo-physicians/covid for alternatives. Temporarily withhold concomitant medications if clinically appropriate. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise stated, interacting medications should be held for 8 days from the first dose of Paxlovid. Very sensitive or narrow therapeutic index CYP3A4 drugs may need to be held for 10 days after the first dose of Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered wi
Pantoprazole Paroxetine Phenobarbital Phenytoin Pimavanserin Pimozide Pioglitazone Pitavastatin Potassium Prasugrel Pravastatin Prednisolone Prednisone Prednisone Primidone Propafenone Quetiapine (reduce by 80%) Quinapril Quinidine	discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paxlovid. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Do not use Paxlovid. Visit https://www.bjc.org/for-physicians/covid for alternatives. Do not use Paxlovid. Visit https://www.bjc.org/for-physicians/covid for alternatives. Temporarily withhold concomitant medications if clinically appropriate. CY93A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise stated, interacting medications should be held for 8 days from the first dose of Paxlovid. Very sensitive or narrow therapeutic index CYP3A4 drugs may need to be held for 10 days after the first dose of Paxlovid Do not use Paxlovid. Visit https://www.bjc.org/for-physicians/covid for alternatives. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovi
Pantoprazole Paroxetine Phenobarbital Phenytoin Pimavanserin Pimozide Pioglitazone Pitavastatin Potassium Prasugrel Pravastatin Prednisolone Prednisone Prednisone Primidone Propafenone Quetiapine (reduce by 80%) Quinapril Quinidine Ramipril Ranitidine	discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paxlovid. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Do not use Paxlovid. Yisit https://www.bic.org/for-physicians/covid for alternatives. Do not use Paxlovid. Yisit https://www.bic.org/for-physicians/covid for alternatives. Temporarily withhold concomitant medications if clinically appropriate. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise stated, interacting medications should be held for 8 days from the first dose of Paxlovid. Very sensitive or narrow therapeutic index CYP3A4 drugs may need to be held for 10 days after the first dose of Paxlovid. Danot use Paxlovid. Misit https://www.bic.org/for-physicians/covid for alternatives. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovi
Pantoprazole Paroxetine Phenobarbital Phenytoin Pimavanserin Pimozide Pioglitazone Pitavastatin Potassium Prasugrel Pravastatin Prednisolone Prednisone Primidone Propafenone Quetiapine (reduce by 80%) Quinapril Quinidine Ramipril	discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paxlovid. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. De not use Paxlovid. Visi https://www.bjc.org/for-physicians/covid for alternatives. Denot use Paxlovid. Visi https://www.bjc.org/for-physicians/covid for alternatives. Temporarily withhold concomitant medications if clinically appropriate. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise stated, interacting medications should be held for 8 days from the first dose of Paxlovid. Very sensitive or narrow therapeutic index CYP3A4 drugs may need to be held for 10 days after the first dose of Paxlovid Bo not use Paxlovid. Visi https://www.bjc.org/for-physicians/covid for alternatives. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. N
Pantoprazole Paroxetine Phenobarbital Phenytoin Pimavanserin Pimozide Pioglitazone Pitavastatin Potassium Prasugrel Pravastatin Prednisolone Prednisolone Prednisone Primidone Propafenone Quetiapine (reduce by 80%) Quinapril Quinidine Ramipril Ranitidine	discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paklovid. Can be co-administered with Paklovid. No interaction expected or interaction is of minimal significance given short Paklovid duration. Can be co-administered with Paklovid. No interaction expected or interaction is of minimal significance given short Paklovid duration. Do not use Paklovid Visit https://www.bjc.org/for-physicians/covid for alternatives. Temporarily withhold concomitant medications if clinically appropriate. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise stated, interacting medications should be held for 8 days from the first dose of Paxlovid. Very sensitive or narrow therapeutic index CYP3A4 drugs may need to be held for 10 days after the first dose of Paxlovid Do not use Paxlovid. Nisit https://www.bjc.org/for-physicians/covid for alternatives. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlov
Pantoprazole Paroxetine Phenobarbital Phenytoin Pimavanserin Pimozide Pioglitazone Pitavastatin Potassium Prasugrel Pravastatin Prednisolone Prednisone Prednisone Primidone Propafenone Quetiapine (reduce by 80%) Quinapril Quinidine Ramipril Ranitidine	discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paxlovid. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Do not use Paxlovid. Visit https://www.bic.org/for-physicians/covid for alternatives. Temporarily withhold concomitant medications if clinically appropriate. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise stated, interacting medications should be held for 8 days from the first dose of Paxlovid. Very sensitive or narrow therapeutic index CYP3A4 drugs may need to be held for 10 days after the first dose of Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given
PantoprazoleParoxetinePhenobarbitalPhenytoinPimavanserinPimozidePioglitazonePitavastatinPotassiumPrasugrelPravastatinPrednisolonePrimidonePropafenoneQuetiapine (reduce by 80%)QuinaprilQuinidineRamiprilRanitidineRanolazineRifabutin (150 mg daily)	discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paxlovid. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Do not use Paxlovid, Visit https://www.bic.org/for-physicians/covid for alternatives. Temporarily withhold concomitant medications of finicially appropriate. CVP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise stated, interacting medications should be held for 8 days from the first dose of Paxlovid. Very sensitive or narrow therapeutic index CVP3A4 drugs may need to be held for 10 days after the first dose of Paxlovid. De not use Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minim
PantoprazoleParoxetinePhenobarbitalPhenytoinPimavanserinPimozidePioglitazonePitavastatinPotassiumPrasugrelPravastatinPrednisolonePrednisonePrimidonePropafenoneQuetiapine (reduce by 80%)QuinaprilQuinidineRamiprilRanolazineRifabutin (150 mg daily)Rifampin	discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paxlovid. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Con be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid discontinued. Unless otherwise tamporarily withhold concomitant medications if clinically appropriate. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise tated, interacting medications should be held for 8 days from the first dose of Paxlovid. Very sensitive or narrow therapeutic index CYP3A4 drugs may need to be held for 10 days after the first dose of Paxlovid Do not use Paxlovid. Mist https://www.bjc.org/fore.physicians/covid for alternatives. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction
PantoprazoleParoxetinePhenobarbitalPhenytoinPimavanserinPimozidePioglitazonePitavastatinPotassiumPrasugrelPravastatinPrednisolonePrimidonePropafenoneQuetiapine (reduce by 80%)QuinaprilQuinidineRamiprilRanitidineRanolazineRifabutin (150 mg daily)	discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paxlovid. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Denot use Paxlovid Misit https://www.bjc.org/for-physicians/covid for alternatives. Denot use Paxlovid Misit https://www.bjc.org/for-physicians/covid for alternatives. Denot use Paxlovid Visit https://www.bjc.org/for-physicians/covid for alternatives. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovi
Pantoprazole Paroxetine Phenobarbital Phenytoin Pimavanserin Pimozide Pioglitazone Pitavastatin Potassium Prasugrel Pravastatin Prednisolone Prednisolone Prednisone Primidone Propafenone Quetiapine (reduce by 80%) Quinapril Quinidine Ramipril Ranitidine Ranolazine Rifabutin (150 mg daily) Rifampin Rifapentine	discontinued. Unless otherwise stated, interacting medications should be managed (doce-reduced/extra monitoring) for 8 days from the first dose of Paxlovid. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Con buse Paxlovid Mish https://www.bjc.org/for-physicians/covid for alternatives. Do not use Paxlovid Mish https://www.bjc.org/for-physicians/covid for alternatives. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlo
PantoprazoleParoxetinePhenobarbitalPhenytoinPimavanserinPimozidePioglitazonePitavastatinPotassiumPrasugrelPravastatinPrednisolonePrednisonePrimidonePropafenoneQuetiapine (reduce by 80%)QuinaprilQuinidineRamiprilRanolazineRifabutin (150 mg daily)Rifampin	discontinued. Unless otherwise stated, interacting medications should be managed (doe-reduced/extra monitoring) for 8 days from the first does of Paxlovid. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Denot use Paxlovid Mist https://www.bic.org/for-abvicians/covid for alternatives. Denotify withhold concomitant medications if clinically appropriate. CVP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise stated, interacting medications should be held for 8 days from the first dose of Paxlovid. Very sensitive or narrow therapeutic index CVP3A4 drugs may need to be held for 10 days after the first dose of Paxlovid Denot use Paxlovid. Mist https://www.bic.org/for-abvicians/covid for alternatives. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duratio
PantoprazoleParoxetinePhenobarbitalPhenytoinPimavanserinPimozidePioglitazonePitavastatinPotassiumPrasugrelPravastatinPrednisolonePrednisonePrimidonePropafenoneQuetiapine (reduce by 80%)QuinaprilQuinaprilRanitidineRanolazineRifabutin (150 mg daily)RifampinRifapentineRimegepant	discontinued. Unless otherwise stated, interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered
Pantoprazole Paroxetine Phenobarbital Phenytoin Pimavanserin Pimozide Pioglitazone Pitavastatin Potassium Prasugrel Pravastatin Prednisolone Prednisolone Prednisone Primidone Propafenone Quetiapine (reduce by 80%) Quinapril Quinidine Ramipril Ranitidine Ranolazine Rifabutin (150 mg daily) Rifampin Rifapentine	discontinued. Unless otherwise stated, interacting medications should be managed (doe-reduced/extra monitoring) for 8 days from the first does of Paxlovid. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Denot use Paxlovid Mist https://www.bic.org/for-abvicians/covid for alternatives. Denotify withhold concomitant medications if clinically appropriate. CVP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise stated, interacting medications should be held for 8 days from the first dose of Paxlovid. Very sensitive or narrow therapeutic index CVP3A4 drugs may need to be held for 10 days after the first dose of Paxlovid Denot use Paxlovid. Mist https://www.bic.org/for-abvicians/covid for alternatives. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duratio
PantoprazoleParoxetinePhenobarbitalPhenytoinPimozidePimozidePioglitazonePitavastatinPotassiumPrasugrelPravastatinPrednisolonePrednisonePrimidonePropafenoneQuetiapine (reduce by 80%)QuinaprilQuinidineRamiprilRanolazineRifabutin (150 mg daily)RifapentineRimegepantRiociguat	discontinued. Unless otherwise stated, interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered
PantoprazoleParoxetinePhenobarbitalPhenytoinPimavanserinPimozidePioglitazonePitavastatinPotassiumPrasugrelPravastatinPrednisolonePrednisonePrimidonePropafenoneQuetiapine (reduce by 80%)QuinaprilQuinidineRamiprilRanolazineRifabutin (150 mg daily)RifapentineRimegepantRiociguatRitonavir – boosted regimens	discontinued. Unless otherwise stated, interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered
PantoprazoleParoxetinePhenobarbitalPhenytoinPimavanserinPimozidePioglitazonePitavastatinPotassiumPrasugrelPravastatinPrednisolonePrednisonePrimidonePropafenoneQuetiapine (reduce by 80%)QuinaprilQuinidineRamiprilRanolazineRifabutin (150 mg daily)RifampinRifapentineRimegepantRitonavir – boosted regimens– monitor for increased	discontinued. Unless otherwise stated, interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Can be co-administered
PantoprazoleParoxetinePhenobarbitalPhenytoinPimozidePioglitazonePitavastatinPotassiumPrasugrelPravastatinPrednisolonePrednisonePrimidonePropafenoneQuetiapine (reduce by 80%)QuinaprilQuinidineRanolazineRifabutin (150 mg daily)RifampinRifapentineRimegepantRitonavir – boosted regimens– monitor for increasedPaxlovid or protease inhibitor	discontinued. Unless otherwise stated, interaction expected or interaction is of minimal significance given short Paskovid duration. Can be co-administered with Paskovid. No interaction expected or interaction is of minimal significance given short Paskovid duration. Danote se Paskovid. With https://www.bic.org/for-physicans/covid for alternatives. Danote se Paskovid. With https://www.bic.org/for-physicans/covid for alternatives. Temporarily withhold concomitant medications if clinically appropriate. CYP3A4 inhibition resolves approximately 3 days after Haskovid is discontinued. Unless otherwise stated, interacting medications should be held for 8 days from the first dose of Paskovid. Danote se Paskovid. With https://www.bic.org/for-physicans/covid for alternatives. Can be co-administered with Paskovid. No interaction expected or interaction is of minimal significance given short Paskovid duration. Can be co-administered with Paskovid. No interaction expected or interaction is of minimal significance given short Paskovid duration. Can be co-administered with Paskovid. No interaction expected or interaction is of minimal significance given short Paskovid duration. Can be co-administered with Paskovid. No interaction expected or interaction is of minimal significance given short Paskovid duration. Can be co-administered with Paskovid. No interaction expected or interaction is generatives. Donot use Paskovid. Mish https://www.bic.org/for-physicians/covid for alternatives. Donot use Paskovid. Mish interaction expected or interaction is of minimal significance given short Paskovid duration. Can be co-administered with Paskovid. No interaction expected or interaction is definence given short Paskovid duration. Can be co-administered with Paskovid. No interaction expected o
PantoprazoleParoxetinePhenobarbitalPhenytoinPimavanserinPimozidePioglitazonePitavastatinPotassiumPrasugrelPravastatinPrednisolonePrednisonePrimidonePropafenoneQuetiapine (reduce by 80%)QuinaprilQuinidineRamiprilRanolazineRifabutin (150 mg daily)RifampinRifapentineRimegepantRitonavir – boosted regimens– monitor for increased	discontinued. Unless otherwise stated, interaction expected or interaction is of minimal significance given short Paskovid duration. Can be co-administered with Paskovid. No interaction expected or interaction is of minimal significance given short Paskovid duration. Danote se Paskovid. With https://www.bic.org/for-physicans/covid for alternatives. Danote se Paskovid. With https://www.bic.org/for-physicans/covid for alternatives. Temporarily withhold concomitant medications if clinically appropriate. CYP3A4 inhibition resolves approximately 3 days after Paskovid is discontinued. Unless otherwise stated, interacting medications should be held for 8 days from the first dose of Paskovid. Danote se Paskovid. With https://www.bic.org/for-physicans/covid for alternatives. Can be co-administered with Paskovid. No interaction expected or interaction is of minimal significance given short Paskovid duration. Can be co-administered with Paskovid. No interaction expected or interaction is of minimal significance given short Paskovid duration. Can be co-administered with Paskovid. No interaction expected or interaction is of minimal significance given short Paskovid duration. Can be co-administered with Paskovid. No interaction expected or interaction is of minimal significance given short Paskovid duration. Can be co-administered with Paskovid. No interaction expected or interaction is generatives. Donot use Paskovid. Mish https://www.bic.org/for-physicians/covid for alternatives. Donot use Paskovid. Mish interaction expected or interaction is of minimal significance given short Paskovid duration. Can be co-administered with Paskovid. No interaction expected or interaction is definence given short Paskovid duration. Can be co-administered with Paskovid. No interaction expected o
PantoprazoleParoxetinePhenobarbitalPhenytoinPimozidePimozidePioglitazonePitavastatinPotassiumPrasugrelPravastatinPrednisolonePrednisonePrimidonePropafenoneQuetiapine (reduce by 80%)QuinaprilQuinaprilRanolazineRifabutin (150 mg daily)RifampinRifapentineRinegepantRiociguatRitonavir – boosted regimens – monitor for increasedPaxlovid or protease inhibitor adverse advents	discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for a days from the first dose of Paslovid. Can be co-administered with Paslovid. No interaction expected or interaction is of minimal significance given short Paslovid duration. Danot use Paclovid Vait thttp://www.bc.org/for-physicans/stowid for atternatives. Temporarily withhold concomiant medications if clinically appropriate. CYP3Ad inhibition resolves approximately 3 days after Paslovid is discontinued. Unless otherwise stated, interaction with the state of the days from the first dose of Paslovid. Very sensitive or narrow therapeutic index CYP3Ad drugs may need to be held for 10 days after the first dose of Paslovid. No interaction expected or interaction is of minimal significance given short Paslovid duration. Can be co-administered with Paslovid. No interaction expected or interaction is of minimal significance given short Paslovid duration. Can be co-administered with Paslovid. No interaction expected or interaction is of minimal significance given short Paslovid duration. Can be co-administered with Paslovid. No interaction expected or interaction is of minimal significance given short Paslovid duration. Can be co-administered with Paslovid. No interaction expected or interaction is of minimal significance given short Paslovid duration. Can be co-administered with Paslovid. No interaction expected or interaction is of minimal significance given short Paslovid duration. Can be co-administered with Paslovid. No interaction expected or interaction is of minimal significance given short Paslovid duration. Can be co-administered with Paslovid. No interaction expected or interaction is of minimal significance given short Paslovid duration. Can be co-administered with Paslovid. No interaction expected or interaction is of minimal significance given short Paslovid duration. Can be co-administered with Paslovid. No interaction expected or interaction is of minimal significance given short Paslovid
PantoprazoleParoxetinePhenobarbitalPhenytoinPimozidePioglitazonePitavastatinPotassiumPrasugrelPravastatinPrednisolonePrednisonePrimidonePropafenoneQuetiapine (reduce by 80%)QuinaprilQuinidineRanitidineRanolazineRifabutin (150 mg daily)RifampinRifapentineRimegepantRitonavir – boosted regimens– monitor for increasedPaxlovid or protease inhibitor	discontinued. Unless otherwise stated, interaction expected or interaction is of minimal significance given short Paskovid duration. Can be co-administered with Paskovid. No interaction expected or interaction is of minimal significance given short Paskovid duration. Danote se Paskovid. With https://www.bic.org/for-physicans/covid for alternatives. Danote se Paskovid. With https://www.bic.org/for-physicans/covid for alternatives. Temporarily withhold concomitant medications if clinically appropriate. CYP3A4 inhibition resolves approximately 3 days after Paskovid is discontinued. Unless otherwise stated, interacting medications should be held for 8 days from the first dose of Paskovid. Danote se Paskovid. With https://www.bic.org/for-physicans/covid for alternatives. Can be co-administered with Paskovid. No interaction expected or interaction is of minimal significance given short Paskovid duration. Can be co-administered with Paskovid. No interaction expected or interaction is of minimal significance given short Paskovid duration. Can be co-administered with Paskovid. No interaction expected or interaction is of minimal significance given short Paskovid duration. Can be co-administered with Paskovid. No interaction expected or interaction is of minimal significance given short Paskovid duration. Can be co-administered with Paskovid. No interaction expected or interaction is generatives. Donot use Paskovid. Mish https://www.bic.org/for-physicians/covid for alternatives. Donot use Paskovid. Mish interaction expected or interaction is of minimal significance given short Paskovid duration. Can be co-administered with Paskovid. No interaction expected or interaction is definence given short Paskovid duration. Can be co-administered with Paskovid. No interaction expected o

r	
Rosuvastatin	Temporarily withhold concomitant medications if clinically appropriate. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise stated, interacting medications should be held for 8 days from the first dose of Paxlovid. Very sensitive or narrow therapeutic index CYP3A4 drugs may need to be held for
Nosavastatin	10 days after the first dose of Paxlovid
Ruxolitinib – consult	Reduce concomitant medication dose, if clinically appropriate and monitor for adverse effects. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is
pharmacist	discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paxlovid.
Salmeterol	Temporarily withhold concomitant medications if clinically appropriate. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise stated, interacting medications should be held for 8 days from the first dose of Paxlovid. Very sensitive or narrow therapeutic index CYP3A4 drugs may need to be held for
	10 days after the first dose of Paxlovid
1 S 2 2 3 3 1 1 1 1 1 1 1 1 1 1	Reduce concomitant medication dose, if clinically appropriate and monitor for adverse effects. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is
	discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paxlovid.
Sertraline	Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Temporarily withhold concomitant medications if clinically appropriate. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise
Sildenafil for ED	stated, interacting medications should be held for 8 days from the first dose of Paxlovid. Very sensitive or narrow therapeutic index CYP3A4 drugs may need to be held for
	10 days after the first dose of Paxlovid
Sildenafil for PH	Do not use Paxlovid. Visit https://www.bjc.org/for-physicians/covid for alternatives.
Silodosin	Temporarily withhold concomitant medications if clinically appropriate. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise stated, interacting medications should be held for 8 days from the first dose of Paxlovid. Very sensitive or narrow therapeutic index CYP3A4 drugs may need to be held for
	10 days after the first dose of Paxlovid
	Temporarily withhold concomitant medications if clinically appropriate. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise
Simvastatin	stated, interacting medications should be held for 8 days from the first dose of Paxlovid. Very sensitive or narrow therapeutic index CYP3A4 drugs may need to be held for 10 days after the first dose of Paxlovid
Circlinum	Due to severity and unpredictability of interaction, Paxlovid is not recommended. For alternatives visit https://www.bjc.org/for-physicians/covid. If Paxlovid is the only
ISITOUTIUS	available option and deemed clinically appropriate, sirolimus should be held with therapeutic drug monitoring used to guide re-initiation.
Sitagliptin	Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration.
Spironolactone	Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration. Do not use Paxlovid. Visit https://www.bjc.org/for-physicians/covid for alternatives.
St. John's wort Sumatriptan	Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration.
	Temporarily withhold concomitant medications if clinically appropriate. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise
Suvorexant	stated, interacting medications should be held for 8 days from the first dose of Paxlovid. Very sensitive or narrow therapeutic index CYP3A4 drugs may need to be held for
	10 days after the first dose of Paxlovid
	Due to severity and unpredictability of interaction, Paxlovid is not recommended. For alternatives visit https://www.bjc.org/for-physicians/covid. If Paxlovid is the only available option and deemed clinically appropriate, tacrolimus should be held with therapeutic drug monitoring used to guide re-initiation.
	Temporarily withhold concomitant medications if clinically appropriate. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise
Tadalafil for ED	stated, interacting medications should be held for 8 days from the first dose of Paxlovid. Very sensitive or narrow therapeutic index CYP3A4 drugs may need to be held for
Tadalafil for PH	10 days after the first dose of Paxlovid Do not use Paxlovid. Visit https://www.bjc.org/for-physicians/covid for alternatives.
	Temporarily withhold concomitant medications if clinically appropriate. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise
Tamsulosin	stated, interacting medications should be held for 8 days from the first dose of Paxlovid. Very sensitive or narrow therapeutic index CYP3A4 drugs may need to be held for
	10 days after the first dose of Paxlovid
	Due to severity and unpredictability of interaction, Paxlovid is not recommended. For alternatives visit https://www.bjc.org/for-physicians/covid. If Paxlovid is the only available option and deemed clinically appropriate, temsirolimus should be held with therapeutic drug monitoring used to guide re-initiation.
	Reduce concomitant medication dose, if clinically appropriate and monitor for adverse effects. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is
	discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paxlovid.
The second second	Temporarily withhold concomitant medications if clinically appropriate. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise
Ticagrelor	stated, interacting medications should be held for 8 days from the first dose of Paxlovid. Very sensitive or narrow therapeutic index CYP3A4 drugs may need to be held for 10 days after the first dose of Paxlovid
Tolvaptan	Do not use Paxlovid. Visit https://www.bjc.org/for-physicians/covid for alternatives.
Tramadol – monitor for both	
	Can be co-administered with caution/monitoring.
Tramadol response	
Trazodone (reduce by 50%)	Reduce concomitant medication dose, if clinically appropriate and monitor for adverse effects. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise stated, interacting medications should be managed (dose-reduced/extra monitoring) for 8 days from the first dose of Paxlovid.
Triamcinolone (nasal)	Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration.
Triazolam	Do not use Paxlovid. Visit https://www.bjc.org/for-physicians/covid for alternatives.
Libraganast	Temporarily withhold concomitant medications if clinically appropriate. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise
Ubrogepant	stated, interacting medications should be held for 8 days from the first dose of Paxlovid. Very sensitive or narrow therapeutic index CYP3A4 drugs may need to be held for 10 days after the first dose of Paxlovid
Valacyclovir	Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration.
Valsartan	Can be co-administered with caution/monitoring.
	Temporarily withhold concomitant medications if clinically appropriate. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise
Vardenafil for ED	stated, interacting medications should be held for 8 days from the first dose of Paxlovid. Very sensitive or narrow therapeutic index CYP3A4 drugs may need to be held for 10 days after the first dose of Paxlovid
Vardenafil for PH	Do not use Paxlovid. Visit https://www.bjc.org/for-physicians/covid for alternatives.
Venetoclax	Do not use Paxlovid. Visit https://www.bjc.org/for-physicians/covid for alternatives.
Venlafaxine	Can be co-administered with Paxlovid. No interaction expected or interaction is of minimal significance given short Paxlovid duration.
Verapamil	Can be co-administered with caution/monitoring.
Vinblastine	Do not use Paxlovid. Visit https://www.bjc.org/for-physicians/covid for alternatives. Do not use Paxlovid. Visit https://www.bjc.org/for-physicians/covid for alternatives.
Vincristine Voclosporin	Do not use Paxlovid. Visit https://www.bjc.org/for-physicians/covid for alternatives.
	Temporarily withhold concomitant medications if clinically appropriate. CYP3A4 inhibition resolves approximately 3 days after Paxlovid is discontinued. Unless otherwise
Vorapaxar	stated, interacting medications should be held for 8 days from the first dose of Paxlovid. Very sensitive or narrow therapeutic index CYP3A4 drugs may need to be held for
Varicanazala	10 days after the first dose of Paxlovid Departure Paxlovid Visit https://www.bic.org/for.physicians/covid.for.phy
Voriconazole Warfarin – monitor INR	Do not use Paxlovid. Visit https://www.bjc.org/for-physicians/covid for alternatives.
closely	Can be co-administered with caution/monitoring.